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The structure of Streptococcus pyogenes uridine phosphorylase (UP) in the 
salvage pathway reveals that it uses different residues to stabilize the transition state.  
Sequence alignment of the enzyme uncovers a subclass of uridine phosphorylases that 
contain these active site residues.  These data, together with the specificity loop of 
uridine phosphorylases, may be used to distinguish between UP and purine nucleoside 
phosphorylase (PNP) enzymes at the level of primary sequence, and thus may allow 
proper annotation.  In Bos taurus, the active site of its purine nucleoside 
phosphorylase can accommodate the major by-product of DNA damage, 
pyrimidopurinone 2'-deoxyribose, and cleave its glycosidic bond.  The base-binding 
site of the enzyme helps explain why the reaction cannot proceed in the reverse 
direction. 
 The structure of a protein complex, ThiS-ThiG, in the thiazole biosynthetic 
pathway was used to rationally design and synthesize a light-activated analog.  
Preliminary characterization of the analog demonstrates that it could be covalently 
linked to ThiS using intein chemistry.  We anticipate that this analog will be of use for 
the structural and mechanistic characterization of thiazole synthase. 
 The crystallization and diffraction screenings of selected enzymes in the 
methionine biosynthetic and sulfur assimilation pathways of Wolinella succinogenes 
 were carried out.  The crystallization conditions for the MetY/homocysteine complex 
have been optimized from 8 Å to 4 Å resolution by screening with different 
cryoreagents.  Detergent screens for the apo-MetY generated small crystals, which 
were used for X-ray diffraction experiments. 
 The MetY structure, which is the first o-acetylhomoserine sulfhydrylase, has 
been determined.  A search for structurally homologous proteins reveals that MetY has 
the same fold as cystathionine gamma lyase and methionine gamma lyase.  The active 
sites of these enzymes, which contain PLP, share a high degree of structural similarity, 
suggesting that MetY belongs to the γ-elimination subclass of Cys/Met metabolism 
PLP-dependent family of enzymes.  The structure of MetY, together with biochemical 
data, provides useful insight to the mechanism of sulfur transfer to a small molecule 
via a protein thiocarboxylate. 
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CHAPTER 1  
INTRODUCTION 
The adage ‘A picture is worth a thousand words’ is true to the core of 
structural biology.  No biologists would deny the importance of the structural 
approach to the field of biology.  Indirect experimental proofs can be quite clever and 
provide useful insight to biology.  Alfred Gilman's novel work on adenylyl cyclase 
represents some of the most creative experiments (1, 2).   However, the element of 
uncertainty and scientific skepticism always remain high in the absence of direct 
evidence.  Gilman did not receive the Nobel Prize until the advent of structures that 
validated his novel experiments.  ‘Seeing is believing’ applies to structural biology as 
well.  Structures themselves can be direct experimental evidence.  The high-resolution 
structure of the potassium channel lends support to its mechanism of potassium 
transport (3).  Structure biology has revolutionized the way biologists think about 
problems.  Structures serve as a guide in designing biological experiments.   
The major tool in structural biology is X-ray crystallography due to its capacity 
to determine large protein structures at high resolution.  Approximately 85-90% of all 
the structures deposited in the PDB were determined by X-ray crystallography.  The 
rest include nuclear magnetic resonance, and electron microscopy.  Especially, in the 
field of enzymology, X-ray crystallography has helped elucidate many interesting, 
complex, ‘impossible’ biochemical transformations that have no precedents in the 
traditional chemical synthesis.  Atomic resolution of substrates in the active sites of 
enzymes have led to design of analogs for various drug targets as well as mechanistic 
studies, such as those for thiamin biosynthesis (4-6) and purine salvage pathway (7).  
Recently, the structure of a neurotransmitter transporter has helped shed light on the 
mechanism of antidepressants in humans (8).  Structures of the sirtuin family of 
proteins revealed the chemical basis of their function, which were proposed to play a 
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major role in aging (9-12).  Without X-ray crystallography, rational drug design would 
not have been possible.  The old combinatorial method of random screens among 
millions of organic compounds for each particular disease would still be the only 
method of choice.   
In spite of many success stories in the field of protein crystallography, many 
challenges face crystallographers today.  Crystallization of membrane proteins and 
macromolecular complexes has been very difficult due to the unique environment in 
which membrane proteins reside and the conformational heterogeneity of protein 
complexes.  Approximately 3% of all the proteins in the PDB (13) are membrane 
proteins to date.  However, this percentage, albeit small, represents significant 
achievements in the field considering that the crystallization of these proteins were 
once thought to be impossible:  “They said it can't be done”--Roderick MacKinnon--a 
membrane protein pioneer who worked out the structure of the potassium channel that 
won him the 2003 Nobel Prize.  G-protein coupled receptor (GPCR) has been studied 
for many years and its structure had eluded researchers, due to the fluidity of seven 
tranmembrane helices with intervening extracellular and intracellular loops, until 
approximately three years ago (14).  The crystal structure of GPCR enabled biologists 
to better understand the mechanism in which the extracellular hormone epinephrine 
induces conformational changes in GPCR, which transmits signal into the cytosol and 
triggers various cancer-signaling pathways.  Thus, the future looks promising for those 
who study membrane proteins and macromolecular complexes.  Approximately, 60-
70% of drugs in the market target membrane proteins.  The number of determined 
structures of membrane proteins has increased exponentially in recent years.  
Considering the number of membrane proteins and protein complexes in the human 
genomes and other species, research opportunities in these areas are seemingly 
endless. 
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The work presented in this dissertation is an application of X-ray 
crystallography to the field of mechanistic enzymology and is categorized into three 
research areas.  The first area focuses on X-ray crystal structures of enzymes in the 
purine/pyrimidine salvage pathway.  The second area utilizes a solved crystal structure 
of a protein complex to design and synthesize substrate analogs to further 
understanding of the thiamin biosynthetic pathway.  The third area also includes 
enzymes in the sulfur assimilation pathway and methionine biosynthesis.  These three 
areas are divided into five chapters. 
Chapter 2 explores the structure of Streptococcus pyogenes uridine 
phosphorylase (SpUP).  This is a key enzyme in the uridine nucleoside salvage 
pathway that catalyzes the reversible phosphorolysis of uridine (2'-deoxyuridine) 
nucleoside into uracil and ribose (2'-deoxyribose) 1-phosphate.  The reverse reaction 
generates nucleosides, which are precursors for RNA and DNA synthesis.  The 
salvage pathway is an alternative pathway to the de novo biosynthetic pathway, which 
consumes much more energy to synthesize RNA and DNA's precursors.  Although 
uridine phosphorylase is present in all organisms, its structure is unique between 
prokaryotes and eukaryotes.  In addition, some parasites, such as Plasmodium 
falciparum, rely entirely on this salvage pathway; thus, it has been an attractive target 
for antimalarial drugs.  Primary sequence alignment (15) of SpUP against the database 
from a BLAST search (16) revealed that the two conserved active site residues of a 
homolog Escherichia coli uridine phosphorylase (EcUP) are not present in SpUP.  
This led to questions regarding the conservation and catalytic mechanism of SpUP 
relative to the proposed one based on known structures of the superfamily.  Thus, the 
crystal structure of SpUP was determined and enzymatic assays of the wildtype and 
mutants were performed to address the questions. 
Chapter 3 relates to Chapter 2 in the sense that it also focuses on the salvage 
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pathway.  However, it examines a purine nucleoside phosphorylase (PNP) structure of 
a higher eukaryote, specifically bovine purine nucleoside phosphorylase (bPNP).  
Structural studies of PNPs are particularly important since the absence of PNP activity 
is linked to T-cell immunodeficiency, due to the accumulation of dGTP, while other 
tissues remain unaffected (17, 18).  Since T-cells are known to mediate autoimmune 
disorders, some cancers, and tissue transplant rejection, PNP has become an important 
drug target.  This chapter examines the crystal structure of the complex containing 
phosphate/sulfate and a guanosine nucleoside analog, pyrimidopurinone 2-
deoxyribose (M1G-dR), which is a major by-product of DNA damage.  The synthesis 
of this analog facilitates biochemical studies of the mechanism of DNA repairs.  
However, its chemical synthesis is challenging due to the lability of glycosydic bond 
under acidic conditions, which are critical for adding and removing protecting groups.  
Thus, PNPs are used in the last step by coupling a sugar moiety and base to generate a 
nucleoside analog.  Interest in studying this complex originates from the difficulty of 
performing the coupling step of this analog using bPNP, while EcPNP can carry out 
the coupling reaction giving 61-64% yield.  Therefore, crystal structures of M1G-
dR/PO4/bPNP and M1G-dR/SO4/bPNP complexes, in which SO4 acts as an unreactive 
mimic of PO4, were determined in order to rationalize the biochemical observations. 
Chapter 4 utilizes a known crystal structure of a protein complex to design and 
synthesize a light-activated inhibitor involved in the biosynthesis of the thiazole 
moiety of thiamin.  Thiamin is an essential cofactor in all living organisms (19).  
Unlike most prokaryotes and some eukaryotes, humans cannot biosynthesize thiamin, 
and thus have to intake 1.4 mg/day from dietary or supplemental sources (20).  The 
interest in synthesizing this inhibitor originates from recent studies of thiazole 
biosynthesis, which suggest that thiazole synthase (ThiG) is covalently linked to a 
sulfur carrier protein (ThiS) by a novel reaction intermediate (21, 22).  This is so far 
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the only known intermediate identified that covalently links two different proteins.  A 
light-activated inhibitor is the ultimate goal because this light activation bypasses the 
removal of protecting groups by chemical means that would precipitate out the 
proteins.  Thus, the whole process of inhibitor design and the actual synthesis were 
carried out and discussed.  In addition, preliminary characterization of the inhibitor 
was performed to demonstrate the proof-of-concept experiments, which utilize intein 
chemistry to covalently link small molecules to ThiS. 
Chapter 5 presents the preliminary crystallographic studies of enzymes in a 
gene cluster containing genes for proteins in methionine biosynthesis and sulfur 
assimilation pathway of Wolinella succinogenes.  This gene cluster was discovered 
from a search for a family of sulfur carrier proteins.  The presence of a sulfur carrier 
protein, HcyS, in this cluster suggests that it somehow links to the sulfur assimilation 
pathway and methionine biosynthesis.  In fact, from our preliminary biochemical 
studies, it was hypothesized that the sulfur from sulfate in the sulfur assimilation 
pathway is transferred into the sulfur carrier protein in the form of a protein 
thiocarboxylate.  Eventually, the sulfur from the protein thiocarboxylate is proposed to 
incorporate into methionine.  In order to further support this hypothesis, initial 
attempts to crystallize selected proteins and protein complexes in the proposed 
pathway were carried out.   
Chapter 6 describes the crystal structure of Wolinella succinogenes o-
acetylhomoserine sulfhydrylase (OAHS), or MetY, one of the enzymes in the gene 
cluster mentioned in chapter four.  MetY is the first structure of an OAHS.  Based on 
our preliminary data, it was proposed that MetY catalyzes the transfer of sulfur from 
the protein thiocarboxylate form of HcyS to o-acetylhomoserine to generate the HcyS-
homocysteine adduct.  From the structure of MetY, together with biochemical data, a 
mechanism of the sulfur transfer catalyzed by MetY has been proposed. 
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CHAPTER 2  
CRYSTAL STRUCTURE OF STREPTOCOCCUS PYOGENES 
URIDINE PHOSPHORYLASE REVEALS A SUBCLASS OF THE 
NP-I SUPERFAMILY THAT UTILIZES DIFFERENT RESIDUES 
TO STABLIZE THE TRANSITION STATE 
Section 2.1 Introduction 
 
Uridine phosphorylase (EC 2.4.2.3) is a key enzyme in the pyrimidine-salvage 
pathway.  The enzyme is present in all organisms and is essential for extracting carbon 
sources from nucleosides (1).  This salvage pathway is an alternative route to the 
energetically expensive de novo biosynthetic pathway, which requires approximately 
ten different biochemical transformations to make precursors for DNA an RNA 
biosynthesis (2).  The enzyme salvages free bases generated by other processes, such 
as apoptosis, to regenerate DNA and RNA precursors as illustrated in Figure 2.1.  
Specifically, uridine phosphorylase catalyzes the reversible phosphorylation of 
ribonucleosides or 2′-deoxynucleosides of uracil (Ura) and their analogs to the 
corresponding nucleobases and (2′-deoxy) ribose-1-phosphate (R1P) as shown in 
Figure 2.2.  Some species, particularly parasites such as Plasmodium falciparum, lack 
the de novo biosynthetic pathway (3, 4).  As a result, these organisms must rely 
entirely on the salvage pathway as a source of nucleosides, making these salvage 
pathways a potential antiparasitic drug target. 
Nucleoside phosphorylases are also known to inactivate certain pyrimidine and 
purine nucleoside analogs that possess anti-tumor properties (5, 6).  Thus, inhibitors 
for these enzymes could enhance the efficacy of the nucleoside analogs.  The 
mechanisms of inhibition by analogs and binding sites in uridine phosphorylases have 
been proposed (7, 8).  Current knowledge of uridine phosphorylase has led to the 
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clinical application of 5-fluorouridine as a chemotherapeutic agent for the treatment of 
advanced stage colorectal cancer (9).  In spite of these studies, the details of the 
chemical mechanism and the role of active site residues are not fully understood.  For 
example, the sulfate ion has been previously used as an unreactive mimic of phosphate 
ion (10) was recently discovered to cleave uridine into two pieces, the ribose 
intermediate and the base (11).  Interestingly, the proposed ribose intermediate exists 
as a glycal, a phenomenon that has not been observed previously in nucleoside 
phosphorylases.  
 
 
 
Figure 2.1.  Generalized de novo pyrimidine biosynthetic and salvage pathways. TP 
stands for thymidine phosphorylase; CMP, UMP, dCMP, dUMP, and dTMP are 
cytidine, uridine, deoxycytidine, deoxyuridine, and deoxythymidine monosphosphate, 
respectively. 
 
In addition to drug design applications, UP can be used as an alternative 
chemical tool in making nucleoside analogs for certain drugs through enzymatic 
synthesis.  Specifically, the glycosidic bond is highly labile in acidic organic solvents.  
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Thus, traditional chemical synthesis of nucleoside analogs becomes quite challenging, 
particularly due to the necessity of adding and removing protecting groups, which lead 
to very low yields. 
 
 
 
Figure 2.2.  Phosphorolysis reaction catalyzed by uridine phosphorylase. 
 
Streptococcus pyogenes is a gram positive bacteria that cause streptococcal 
illnesses that vary based on the location of infection (12).  SpUP contains 259 amino 
acids per monomer with a molecular weight of 27.8 kD.  Multiple sequence 
alignments (13) of SpUP against the nonredundant BLAST (14) database revealed a 
surprising result.  The two critical active-site arginine residues found in EcUP, which 
has 39% sequence identity with SpUP, were not present in SpUP or a number of other 
UP’s from diverse branches of the phylogenetic tree of the UP superfamily.  The 
sequence alignment suggests that SpUP belongs to the NP-I family of proteins and 
thereby shares a common α/β fold with hexameric and trimeric purine nucleoside 
phosphorylases, adenosine monophosphate nucleosidase, methylthioadenosine 
nucleosidase, and methylthioadenosine phosphorylases (6, 15). 
In this report we present the X-ray structures of SpUP in complex with the 
products (R1P/Ura) and the substrate uridine (Urd) at 1.8 Å and 2.2 Å, respectively.  
The three-dimensional structure shows that the overall monomeric fold is similar to 
nucleoside phosphorylase I (NP-I) superfamily.  The structures of these complexes 
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shed light on the mechanism of catalysis in the absence of two critical active site 
arginine residues, which are hypothesized to stabilize the transition state of EcUP.  In 
addition, these studies provide useful insight to the relationship of SpUP to other 
members of the NP-I superfamily. 
Section 2.2  Experimental 
Molecular cloning of native SpUP.  The up gene was PCR amplified from 
Streptococcus pyogenes (ATCC 12344) genomic DNA using the following primers: 
upstream primer 5'-GGG TAG CAT ATG CAA AAT TAT TCA GGT GAA GTC 
GG-3' (inserts an NdeI site at the start codon of the up open reading frame); 
downstream primer 5'-CCC TAC TCG AGT TAT TGT GAT TTA TCA TTT TCA 
ATA AG-3' (inserts an XhoI site after the end of the up open reading frame).  The 
purified PCR product was digested with NdeI and XhoI, purified and ligated into 
similarly digested pTHT (which is a pET-28 derived vector which allows attachment 
of a modified 6xHisTag followed by a TEV protease cleavage site onto the N-terminus 
of the expressed protein).  Colonies were screened for presence of the insert and a 
representative plasmid was designated pSpUP.THT.  The PCR-derived DNA was 
sequenced and shown to contain no errors. 
Standard methods were used for DNA restriction endonuclease digestion, 
ligation and transformation of DNA (16, 17).  Automated DNA Fluorescence 
Sequencing was performed at the Cornell BioResource Center.  Plasmid DNA was 
purified with the GeneJet miniprep kit (Fermentas, Glen Burnei, MD).  DNA 
fragments were separated by agarose gel electrophoresis, excised and purified with the 
Zymoclean gel DNA recovery kit (Zymo Research, Orange, CA).  E. coli strain MachI 
(Invitrogen, Madison, WI) was used as a recipient for transformations during plasmid 
construction and for plasmid propagation and storage.  An Eppendorf Mastercycler 
and Phusion DNA polymerase (New England Biolabs, Ipswich, MA) were used for 
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PCR.  All restriction endonucleases and T4 DNA ligase were purchased from New 
England Biolabs (Ipswich, MA).  E. coli strain BL21(DE3) and the pET 
overexpression system were purchased from Novagen (Madison, WI).  
 Expression and purification of native SpUP.  The plasmid described above was 
transformed into expression strain BL21(DE3) E. coli cells.  An overnight culture of 
10 mL was grown in lysogeny broth media at 37°C supplemented with 50 µg/mL 
kanamycin, and then introduced into 1 L volume containing 50 µg/mL kanamycin.  
The 1L cell culture was shaken at 37°C and 200 rpm until the OD600 reached 0.6, at 
which point the temperature was reduced to 15°C and 1 mM of isopropyl-1-β-D 
galactopyranoside (IPTG) was added.  Approximately 16 hours later, the cells were 
harvested by centrifugation at 7459 g for 20 minutes.  The pellet was stored at –80 °C.   
 The frozen cell pellet was thawed overnight at 4°C.  Approximately 30 mL of 
lysis buffer (20 mM Tris pH 8, 10 mM imidazole, and 300 mM NaCl) were added to 
the pellet to solubilize it.  The cell suspension was sonicated and then centrifuged at 
47, 488 g for 1 hour at 4°C to remove the cell debris.  The clarified lysate was loaded 
onto a pre-equilibrated Ni-NTA gravity column, after which the column was rinsed 
with 20 column volumes of the same lysis buffer.  SpUP was then eluted with 10 mL 
of elution buffer (20 mM Tris pH 8, 300 mM imidazole, 10% glycerol, and 300 mM 
NaCl).  The eluted protein was loaded directly onto a size exclusion column 
(Pharmacia G200 superdex, hiload) for further purification.  The protein fractions 
from the column were pooled together and concentrated to 25-30 mg/mL using an 
Amicon Ultra centrifugal filter.  The SpUP concentration was determined by the 
method of Bradford (16).  The protein was confirmed to be at least 95% pure by SDS-
PAGE.  The pure protein was buffer exchanged into 20 mM Tris pH 8, 50 mM NaCl, 
and 1 mM DTT, flash frozen with liquid nitrogen and stored at –80 °C.   
Crystallization experiments.  The frozen protein was thawed at 4°C and 
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incubated for 12 hours with 8 mM of either Urd plus ammonium sulfate (A.S.). in Tris 
buffer pH 8 or 8 mM R1P in Tris buffer pH 8 with 2 mM of Ura in 5% DMSO.  Co-
crystallization trials were initially carried out by vapor diffusion hanging drop method 
at 22°C, using sparse matrix screening solutions (Hampton Research, Emerald 
Biosystems). 1 µl of the protein solution was combined with an equal volume of well 
solution.  The R1P/Ura/SpUP complex crystallized in 0.1 M sodium citrate pH 5.2, 
18% (w/v) PEG 4000, and 16% isopropanol.  The sizes of these crystals vary from 
(0.03 mm x 0.1 mm x 0.2 mm) to (0.1 mm x 0.2 mm x 0.45 mm).   For the 
Urd/A.S./SpUP complex, crystals grew in 0.1 M Hepes, pH 7.8, 20% isopropanol, and 
18% (w/v) PEG 4000.  The crystal sizes vary within the same range as those of the 
product bound complex.  The crystals for both complexes, which were plate like or 
blocky in shape took 3-7 days to grow.  Although crystals were grown for other ranges 
of pH or other precipitant conditions, these crystals were either very small or grew in 
clusters due to fast nucleation.  Since one of the precipitant reagents, isopropanol, is 
very volatile, it was later replaced by 2-methyl-2,4-pentanediol.  As a result, the 
crystals became much smaller and lower in quality.  Other crystallization conditions 
gave needles or needle clusters.  Nevertheless, the electron density for the uridine of 
the Urd/A.S. complex was very poor.  Therefore, crystals from a different 
crystallization condition, (0.1 M Tris pH 7.3 and 31% (w/v) PEG 1000), were soaked 
with 8 mM of uridine. 
 Data Collection and Processing.  Both of the product-bound (R1P/Ura) and 
the substrate-bound (Urd) complexes were collected at the 24-ID-C station of NE-
CAT beam line at the Advanced Photon Source (APS) at Argonne National 
Laboratory using an ADSC (Area Detector system Corp.) Quantum 315 detector.  The 
data were collected at 0.97849 Å over 360° using a 0.5° oscillation range.  A 
cryoprotectant solution of 10% glycerol in the mother liquor was used for the crystals 
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of the uridine complex.  All the data sets were indexed, integrated, and scaled using 
the HKL2000 program suite (18).  The data collection statistics are shown in Table 
2.1. 
Structure Determination.  Using the EcUP structure (1K3F) (19) as the search 
model, the SpUP structure was solved by molecular replacement using REFMAC5 
program of the CCP4 program suits (20). CHAINSAW in the CCP4 suite was used to 
remove all the side chains of the molecular replacement.  After one around of tight 
restrained refinement, the Rfactor and Rfree dropped significantly to 32.4% and 34.7%, 
respectively.  In subsequent rounds of refinements, the restraints were gradually 
relaxed.  Most of the side chains were built in during these rounds of refinement.  
Further refinements were performed in CNS (21), starting with rigid body refinement, 
stimulated annealing, B-factor refinement, and finally energy minimization.  
Difference Fourier map, 1Fo-Fc, 2Fo-Fc, and composite omit maps were calculated 
from models with all ligands removed after each round of refinement.  Manual model 
building was done successively using COOT (22) and the NCS-averaged composite 
omit map to minimize model bias.   Only after the Rfactor and Rfree converged were 
water molecules added.  The ligands were modeled into the active site of each chain of 
their corresponding SpUP complexes.  The ligands were generated using PRODRG 
(23).  The geometry of SpUP was validated using PROCHECK (24).  Figures were 
generated using Pymol and ChemBioDraw (25).  The refinement statistics are 
tabulated in Table 2.2. 
 16 
 
Table 2.1. Data Collection Statistics for Uridine Phosphorylase Complexes. 
 
 Urd R1P/Ura 
beamline APS NE-CAT 24-ID-C APS NE-CAT 24-ID-C 
wavelength (Å) 0.97849 0.97849 
resolution (Å) 2.2 1.8 
space group  P21 P1 
molecules / a.s.u. 1 3 
a (Å) 90.9 90.0 
b (Å) 81.7 91.7 
c (Å)  123.4 169.3 
α (°) 90.0 78.5 
β (°) 99.2 82.3 
γ (°) 90.0 60.1 
measured reflections 220163 793731 
unique reflectionsa 82371 (8372) 404352 (16027) 
average I / σa 13.5 (2.9) 19.3 (4.1) 
redundancya 2.7 (2.6) 2.0 (1.9) 
completeness (%)a 91.2 (93.6) 94.6 (74.7) 
Rsym (%)a,b 9.5 (37.5) 4.9 (20.5) 
aValues for the highest-resolution shell are given in parentheses. 
bRsym = ΣΣi | Ii − <Ι> | / Σ <Ι>, where <Ι> is the mean intensity of the N reflections 
with intensities Ii and common indices h,k,l. 
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Table 2.2.  Data Refinement Statistics for Uridine Phosphorylase Complexes 
 
 Uridine Ura/R1P 
resolution (Å) 2.2 1.8 
no. of protein atoms 10915 33759 
no. of ligand atoms 102 396 
no. of water atoms 344 2750 
reflections in working set 78069 383726 
reflections in test set 4249 20277 
R-factora (%) 19.6 17.7 
Rfreeb (%) 22.4 20.3 
rmsd from ideals   
     bonds (Å) 0.007 0.005 
     angles (°) 1.328 1.283 
avg B factor (Å2) 25.5 12.0 
Ramachandran Plot   
     most favored (%) 90.4 92.4 
     additionally allowed (%) 8.8 7.1 
     generously allowed (%) 0.8 0.5 
     disallowed (%) 0 0 
aR-factor = Σhkl| |Fobs| − k |Fcal| | / Σhkl |Fobs| where Fobs and Fcal are observed and 
calculated structure factors, respectively. 
bFor Rfree, the sum is extended over a subset of reflections (5%) excluded from all 
stages of refinement. 
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Section 2.3 Results 
Quaternary Structure of SpUP.  As expected from its 39% sequence identity 
with EcUP, the biological unit of SpUP is a hexamer having 32 symmetry (Figure 
2.3a).  The toroidal hexamer has a diameter of approximately 100 Å and a thickness of 
40 Å.  The hexamer of SpUP also has a central channel of 18 Å in diameter.  To date 
all the known prokaryotic members of the NP-1 superfamily have the hexameric 
quaternary structure.  The oligomeric state is also confirmed by the size exclusion 
chromatography data, which estimated the molecular weight of the SpUP oligomer to 
be approximately 167 kDa, the weight of six SpUP protomers.  Three hexamers are 
found in the asymmetric unit of the R1P/Ura complex and one hexamer for the Urd 
complex.  While each protomer contains an active site, the active site is located at a 
dimer interface and contains two residues from the adjacent monomer.  Thus, the 
minimal functional unit is a dimer.  The distance between two active sites, which are 
located on opposite faces of the hexamer, is about 21 Å.  The interactions between 
each dimer of the hexamer are primarily hydrophobic.  The 170-182 loop contains 
several residues that participate in polar dimer-dimer interactions. 
Structure of SpUP Protomer.  As in the case of EcUP (26), the SpUP protomer 
shown in Figure 2.3b adopts an α/β fold.  The core contains a mixed, twisted eight-
stranded β-sheet in the following orientation: β2↑β3↓β4↑β1↑β5↑β10↑β8↓β6↓.  The β-
sheet is flanked on both sides by six α-helices with α1, α4 and α9 on one side and α2, 
α3 and α7 on the other.  β2, β5 and β10 are relatively longer than the rest of the β 
strands, containing nine, ten, and eight residues, respectively.  Alpha helices, α5, α6 
and α8 as well as a 310 helix (η1) are clustered on one side of the active site.  Four α 
helices, α2, α4, α6, and α9 are much longer than the rest. α9 capping the C-terminus, is 
the longest consisting of 17 residues whereas helices α2, α4, and α6 contain 11, 13, and 
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13 residues, respectively.  The loop between α8 and α9, residues 234-238, is generally 
disordered.  The accompanying topology diagram is shown in Figure 2.3c. 
 
 
Figure 2.3.  Structures of SpUP. (a) Hexameric quaternary structure of SpUP color-
coded to emphasize the 32 point symmetry or a trimer of dimers.  Six subunits are 
labeled A to F.  (b) SpUP protomer with the bound products, R1P and Ura, shown in 
the active site.  The helices are labeled red, the strands yellow, and the loops green, 
respectively.  The N-terminus and the C-terminus are also indicated with letters N and 
C.  (c) Topology diagram of SpUP protomer.  The colors of the helices and strands are 
the same as Figure 2.1b, except the loops is colored as black lines.  The beginning and 
end residues of each secondary structure are indicated by numbers. 
 
Phosphate Binding Site.  The stereo figure of the R1P/Ura complex in Figure 
2.4 reveals the details of the active site at 1.82 Å resolution.  The most significant 
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feature of the phosphate binding site is the presence of three highly conserved arginine 
residues, Arg33, Arg51, and Arg 94.  Arg51 comes from a neighboring monomer.  
The three arginine residues hold the phosphate moiety of R1P in place with a strong 
ionic network.  Two other conserved residues, Gly29 and Thr97, also hydrogen bond 
to the phosphate group.  In addition, one of the oxygen atoms of the phosphate ion 
closest to the ribose also forms a hydrogen bond to O3′ of the sugar. 
 
 
Figure 2.4.  Stereo diagram of the active site containing R1P and ura inside the 2 Fo-Fc 
map contoured at 2.5 σ.  The red spheres represent water molecules. 
 
 Ribose Binding Site.  Figures 2.4 and 2.5 show the ribose binding site 
containing another conserved residue His13 from the adjacent monomer.  This residue 
hydrogen bonds to the hydroxyl group of C5′ from the upper face, or beta face, of the 
ring.  Thr97 makes a second hydrogen bond with the O4′ of the ribose ring.  The 
hydroxyl group at C2′ forms two hydrogen bonds to Arg94 and Glu198, which involve 
the main interactions with the sugar by forming a bidentate with the 2′ and 3′ hydroxyl 
groups.  The sulfur atom of the highly conserved Met197 interacts hydrophobically 
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with the hydrophobic beta face of the ribose, perhaps positioning the substrate in the 
active site.  In addition, the main-chain nitrogen of Met197 hydrogen bonds to the 2′ 
hydroxyl group.  A conserved water molecule nearby also hydrogen bonds to the O4′ 
of the sugar.  The water molecule in the Urd complex shown in Figure 2.5 is not 
conserved.  In the absence of the phosphate substrate, the water masks the position of 
one of the oxygen atoms of the phosphate ion.   
 
 
 
 
Figure 2.5.  Stereo diagram of SpUP in complex with the substrate uridine showing 
the 2 Fo-Fc electron density map contoured at 2.5 σ. 
 
 Uracil Binding Site.  It is within the base binding site that we observe His169 
and Lys162 in the active site.  These residues have not been observed in any known 
structures of the UP superfamily.  His169 is located approximately 3 Å away from the 
O4 of the uracil and approximately 60° above the plane of the uracil ring.  A Lys162 
residue hydrogen bonds to O2 and N3 of the uracil.  Gln168 is strictly conserved 
among all the known NP-I structures and makes hydrogen bonds with the N3 
hydrogen and O4 of the uracil base.  Phe165 forms a herringbone interaction with the 
aromatic ring of the uracil.  Val220 interacts with the hydrophobic portion of the uracil 
ring. 
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 Uridine Phosphorolysis Assay.  Based on the crystal structure of SpUP, several 
point mutations were made to probe the critical residues in the base-binding region of 
the active site.  Lys162 was mutated to alanine, and His169 was mutated to alanine, 
asparagine, and aspartate.  In addition, Val220 was mutated to aspartate and glutamate 
to see if the enzyme could accommodate a purine base in the presence of these 
charged groups.  The results are shown in Table 2.3. 
 
Table 2.3.  Uridine Phosphorolysis Assay Results for SpUP and Mutants 
 
 
SpUP Uridine cleavage activities 
  (nmoles / mg / hr) 
Wildtype 1,500,000 
K162A 20 
H169A 112,000 
H169D 9,000 
H169N 42,000 
V220D 550 
V220E 3,400 
 
Section 2.4 Discussion 
Overall structure of SpUP.  The biological unit of SpUP is a hexamer as 
expected for a prokaryotic uridine phosphorylase (Figure 2.3a).  Only one hexamer is 
present in the asymmetric unit of the Urd complex.  However, three hexamers are 
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found in the asymmetric unit of the R1P/Ura complex.  One of these hexamers is 
slightly twisted in relation to the others such that the packing results in the lowest 
symmetry P1 space group (Table 2.1).  Since each active site of the hexamer contains 
two conserved residues from an adjacent monomer at each dimer interface, the 
minimal functional unit is a dimer. 
 
Figure 2.6.  Superposition of the active sites of SpUP (green) and EcUP (magenta).   
 
The SpUP protomer superposes very well on the EcUP protomer, especially in 
the active site as shown in Figure 2.6.  This nearly identical superposition of the active 
sites is interesting considering only 39% sequence identity between the two UPs.  
Furthermore, like EcUP, SpUP adopts the same universal monomeric α/β fold of all 
known nucleoside phosphorylases.  Hence, SpUP most likely possesses the same 
mechanism of phosphorolysis, in which the uridine undergoes a unimolecular 
substitution via the formation of a high-energy ribosyloxocarbenium ion intermediate.  
Residues 170-182 including the 310 helix (η1) and part of α6 constitute the signature 
loop (27), which allows only nucleosides containing one-ring bases such as uridine, 
thymidine, and their derivatives to bind to the active site.  The primary sequence 
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alignment demonstrating this so-called specificity loop is shown in Figure 2.7.  As 
shown in the figure, SpUP has two less residues in the specificity region compared 
with EcUP.  However, this loop is missing in EcPNP.  Thus, the space occupied by 
this loop allows PNP to accommodate large-ring purine bases. 
 Uridine Phosphorolysis Assay.  As seen in Table 2.4, the most noticeable 
feature is the activity of K162A mutant, which is near the assay's detection limit.  
Clearly, Lys162 is required for SpUP activity.  However, the enzyme still maintains a 
low level of activity with histidine mutants that do not carry a negative charge, H162A 
and H162N.  Hence, His169 is not as critical as Lys162.  Furthermore, the presence of 
a negative charge at Val220 is also detrimental to the enzyme as seen in V220D and 
V220E mutants.  These mutational data suggest that during the transition state, the 
negative charge delocalizes over C2, C5, and C6 of the uracil ring as expected.  This 
negative charge repels any nearby negatively charged residues, and destabilizes or 
ultimately inhibits the phosphorolysis reaction.  Accordingly, positively charged 
residues are predicted to enhance the rate of the phosphorolysis, or at least increase the 
binding affinity of the enzyme for the substrate.  However, this coulombic interaction 
in the active site of SpUP would require a delicate balance because too strong of an 
electrostatic interaction would hinder the product release step.  Accordingly, the 
reaction would then prefer to shift toward the synthesis direction. 
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Figure 2.7.  Specificity region (residues 170-182) of SpUP is revealed by the 
alignment of SpUP against EcUP and EcPNP. 
Comparison of the Active Sites of SpUP and EcUP.  Having the same fold as 
that of EcUP (8) is translated into nearly identical active site residues in this particular 
case, despite sharing only 39% sequence identity (Figure 2.6).  The structure of EcUP 
crystallized with R1P/Ura (1TGY) was used for comparison.  As seen in Figure 2.4, 
the active sites and, in particular, the ligands of the two structures superimpose very 
well.  The individual active-site residue comparison is shown in Table 2.4.  In 
addition, the active site of EcUP has an equivalent arginine (Arg48) and a histidine 
(His8) from the neighboring monomer, which correspond to Arg51 and His13 of 
SpUP.  Single-site mutagenesis studies by Oliva et. al. (28) showed that the His8Ala 
mutation in EcUP reduced the enzyme’s activity to 21% compared to the wild type 
(Table 2.5).  This mutation indicates that His8 or His13 in SpUP binds and stabilizes 
the ribose moiety in addition to its role in subunit interaction. 
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Table 2.4.  Comparison of active site residues between EcUP and SpUP. 
 
 EcUP SpUP 
   
Phosphate Gly26 Gly29 
 Arg30 Arg33 
 Arg48* Arg51* 
 Arg91 Arg94 
   
Ribose His8* His13* 
 Arg91 Arg94 
 Thr94 Thr97 
 Met197 Met197 
 Glu198 Glu198 
   
Uracil -------- Lys162 
 Phe162 Phe165 
 Gln166 Gln168 
 Arg168 His169 
 Ile220 -------- 
 Val221 Val220 
 Arg223 -------- 
 
* = residues from the neighboring monomer 
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As indicated in Table 2.4 and Figure 2.6, the two base binding sites differ to 
some extent.  SpUP has conserved residue Gln168 which hydrogen bonds with N3H 
and O4 of the uracil base.  Mutation of its equivalent, Gln166 in EcUP, to alanine 
inactivated the enzyme (Table 2.5).  However, the Gln166Asp mutation lowered the 
activity to 30% of the wild type while Gln166Ala mutation completely inactivated the 
enzyme.  This substitution demonstrates that Gln166 in EcUP or Gln168 in SpUP is 
required for hydrogen bonding to the base.  Phe165 of SpUP, similar to Phe162 in 
EcUP, forms a herringbone stacking interaction with the aromatic ring of the uracil.  
The Phe162Ala substitution in EcUP abolished the activity indicating that Phe162 
(Phe165 in SpUP) is required to position and stabilize the base.  Val220 interacts with 
the nonpolar side of the uracil ring.  No equivalent of Ile220 in EcUP exists in SpUP.  
Nevertheless, two water molecules are present nearby, which most likely mark the 
solvent path leading to the surface of the protein.  Both Glu198Asp and Glu198Gln 
mutations completely inactivate EcUP (Table 2.5).  These data imply that hydrogen 
bonding to the hydroxyl groups of the sugar cannot account for the function of Glu198 
in either EcUP or SpUP.  Thus, the correct chain length is critical and the negative 
charge is required for catalysis.  These mutations clearly support the hypothesis for the 
transition state, which was proposed to contain a continuum of electrostatic 
interactions for both EcUP and SpUP, as shown in Figures 2.8a and 2.8b. 
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Table 2.5. Characterization of single amino acid mutants of uridine phosphorylase. 
 
Expressed 
proteinsa 
Activity  
(U/mL extract) 
Total protein 
(mg/ml) 
Specific 
activity 
(U/mg total 
proteins) 
Percent of 
wild type 
activity 
Wild-type UP 540 24 22.5 100 
-- 0 12 0.0 0 
His8Ala 150 31 4.8 21 
Arg30Ala 5 15 0.3 1 
Arg30Lys 17 14 1.2 5 
Ile69Ala 900 36 25.0 111 
Arg91Ala 0 13 0.0 0 
Arg91Lys 11 23 0.5 2 
Thr94Ala 5 14 0.4 2 
Phe162Ala 0 33 0.0 0 
Tyr195Ala 378 14 27.0 120 
Tyr195Gly 5 12 0.4 2 
Gln196Ala 0 37 0.0 0 
Gln196Asp 84 11 7.6 34 
Met197Ala 150 37 4.1 18 
Met197Ser 32 14 2.3 10 
Glu198Gly 0 23 0.0 0 
Glu198Asp 0 13 0.0 0 
Glu198Gln 0 32 0.0 0 
aThe activity of wild-type UP produced by pGM679 is reported.  UP produced by 
pGM870 showed less than 2% difference.  The negative control is pUC18. 
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Figure 2.8.  Transition state stabilization of high energy intermediates of the 
phosphorolysis reaction in EcUP (a) and SpUP (b) by a continuum of electrostatic and 
hydrogen bond interactions as illustrated by the dotted line. 
 
The most obvious difference between the two active sites is the superposition 
of His169 of SpUP with Arg168 of EcUP.  In addition to this residue, Lys162 
hydrogen bonds to O2 of the uracil base.  These two residues that directly interact with 
a base have not been observed in any known UP structures.  This raises two questions. 
Are these two residues conserved, and if so what role do they play in the transition 
state of the phosphorolysis reaction?  The fact that Lys162 hydrogen bonds to O2 of 
the uracil suggests that the negative charge resulting from the glycosidic bond 
cleavage may reside mostly on the O2.  Arg168 in EcUP was proposed to be involved 
in the binding to the uracil base (27).  The authors suggested that Arg168 might 
control the substrate specificity.  The proposed transition state for the phosphorolysis 
reaction of EcUP is shown in Figure 2.8a.  Similarly to Arg168, the imidazole ring of 
His169 in the active site of SpUP probably possesses a positive charge and plays the 
same role as Arg168 by controlling the substrate specificity (Figure 2.8b).  The 
imidazole ring of His169 cannot form a hydrogen bond with the O4 of the uracil to 
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any appreciable extent due to its unfavorable geometry at approximately 60 degrees 
above the plane of the uracil ring.  Arg168 in EcUP is actually more able to make the 
hydrogen bond due to its greater degree of freedom of the sp3 hybridized nitrogen.  
Instead, His169 most likely interacts electrostatically with the O4 of the uracil.  
However, the electrostatic interaction of His169 would be weaker than Arg168 of 
EcUP because the developing negative charge presumably delocalizes primarily on the 
O2 of the uracil ring in SpUP, whereas the negative charge resides primarily on the O4 
of the uracil ring in EcUP.  If this electrostatic stabilization hypothesis is correct, then 
a R168E mutation in EcUP or a H169E mutation in SpUP would severely destabilize 
the transition state and thus would inactivate the corresponding enzyme due to 
negative charge repulsion between the new glutamate side chain and the developing 
negative charge on the uracil base.  This hypothesis is supported by the results of the 
uridine phophorolysis assay (Table 2.3) for the His169 mutants.  The H162D mutant 
exhibits at least an order of magnitude lower activity than the H162A mutant.  In 
addition, the R168A mutation in EcUP and the H169A mutation in SpUP are expected 
to be less detrimental than the corresponding R168E mutation in EcUP and H169E 
mutation in SpUP due to the lack of negative charge repulsion.  Nevertheless, the 
R168A mutation is expected to be more detrimental to EcUP than the equivalent 
H169A mutation in SpUP because the negative charge resides mostly on the O4 of the 
uracil ring in EcUP.  Therefore, Lys162 is, in all probability, the critical residue in 
stabilizing the transition state and perhaps donates a hydrogen atom to the leaving 
uracil base. 
 Caradoc-Davies and colleagues (27) also speculated that the reason that EcUP 
does not cleave cytidine is because of the assumed positive charge on N4 of the 
cytosine base will be repelled by Arg168.  This hypothesis seems less plausible 
because the pKa of the N4 of cytidine is 4.2.  At physiological pH, the N4 is unlikely 
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to carry a positive charge unless the local pH drops below 4 during catalysis.  
Incidentally, this would also support the protonated form of the aspartic acid residue 
found in the base binding pocket of most structurally characterized NP-I enzymes.  
Hence, a more conclusive explanation for the lack of reactivity of cytidine remains to 
be discovered. 
 Another interesting feature regarding the active site of SpUP is observed based 
on structural superposition of the R1P/Ura complex, Urd complex, and sulfate ion 
complex (not shown).  Assuming that the product bound complex takes on the closed 
conformation, the active site is in the closed form upon the binding of any of either the 
phosphate or Urd or R1P/Ura.  In other words, the active site must be occupied by at 
least one ligand in order for SpUP to assume a closed conformation.  
Significance of the SpUP Structure.  Comparing of the active sites of SpUP 
and EcUP suggests that the two enzymes have the same transition state.  However, 
SpUP utilizes different residues to stabilize the negative charge on the base.  Hence, 
the next question to ask is whether this difference is unique in SpUP or it also exists in 
other species.  A multiple sequence alignment of SpUP and EcUP with sequences 
found using a BLAST search against the nonredundant database was performed using 
CLUSTAL W (13) is shown in Figure 2.9.  Among all the representative species in the 
alignments, 22 out of 53 sequences contain the Lys and His residues equivalent to 
K162 and H169 of SpUP.  None of these have the equivalents of Arg168 and Arg223 
of EcUP.  The other 31 sequences, including EcUP, show the reverse.  These 31 
enzymes possess the two equivalent arginine residues, but none of them have the 
equivalent K162 and H169 of SpUP.  The phylogenetic tree of all the sequences from 
the alignments is shown in Figure 2.10.  With the exception of three species, 
Sebaldella termitidis, Desulfonatronospira thiodismutans, and Francisella tularensis, 
all the species colored red, or SpUP-like species, are clustered together.  The same is 
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true for those in blue, or EcUP-like species.  This suggests a new way of clustering of 
UP's. 
 
 
 
 
Figure 2.9.  Multiple sequence alignment of uridine phosphorylase superfamily. The 
amino acids highlighted in red and blue are critical active site residues found in SpUP 
and EcUP, respectively. 
 
These structural studies of SpUP led to the discovery of a subclass of UP’s that 
utilize different active-site residues to stabilize the transition state.   Furthermore, the 
two discriminating residues, Lys162 and His169, together with UP's specificity loop  
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Figure 2.10.  Phylogenetic tree of uridine phosphorylase superfamily from Figure 2.6 
applying the same color-coding scheme. 
 
may be used to distinguish between UP and PNP enzymes at the level of primary 
sequence, and thus may allow proper annotation. 
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CHAPTER 3  
 CRYSTAL STRUCTURE OF BOVINE PURINE NUCLEOSIDE 
PHOSPHORYLASE IN COMPLEX WITH PYRIMIDOPURINONE 2'-
DEOXYRIBOSE AND PHOSPHATE/SULFATE ION  
Section 3.1 Introduction 
Purine nucleoside phosphorylase (PNP; EC 2.4.2.1) is an indispensable 
enzyme in the purine salvage pathway that catalyzes the reversible phosphorolysis of 
ribonucleosides or 2'-deoxyribonucleosides to ribose or 2'-deoxyribose 1-phosphate 
(R1P or dR1P) and the free base (Figure 3.1).   
 
 
 
Figure 3.1. Phosphorolysis reaction catalyzed by purine nucleoside phosphorylase . 
 
The salvage pathway is an alternative pathway to the de novo purine 
biosynthetic pathway, which undergoes approximately ten different biochemical 
transformations to make precursors for DNA and RNA biosynthesis (Figure 3.2).  This 
enzyme catalyzes an important first step in all organisms and various tissue types by 
extracting carbon source from free purine bases and nucleosides (Parks & Agarwal, 
1972, Leer et al., 1977).  Some parasites, such as Plasmodium falciparum, lack the de 
novo biosynthetic pathway (Hassan, 1988, Schnick, 2005).  As a result, these 
organisms must rely entirely on the salvage pathway as a source of nucleosides, 
making these salvage pathways potential antiparasitic drug targets.  Furthermore, the 
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absence of PNP activity is linked to T-cell immunodeficiency due to the accumulation 
of dGTP, while other tissues remain unaffected (Giblett et al., 1975, Hershfield & 
Mitchell, 1995).  Since T-cells are known to mediate autoimmune disorders, some 
cancers, and tissue transplant rejection, PNP has become an important drug target.  
 
 
Figure 3.2. Generalized de novo purine biosynthetic and salvage pathways. AMPN 
stands for adenosine monophosphate nucleosidases, and AMP, IMP, XMP, CMP 
adenosine, inosine, xanthine, and cytosine monophosphate, respectively.  The green 
arrow indicates that the transformation is unique to prokaryotes. 
 
Although PNP enzymes have been studied more extensively than uridine 
phosphorylase (UP) enzymes, the details of the chemical mechanism and the role of 
active site residues is not fully understood.  For example, the sulfate ion, which has 
been previously used as an unreactive mimic of phosphate ion (Federov et al., 2001), 
was recently discovered to cleave uridine into two pieces in bovine UP, the ribose 
intermediate and the base (Paul et al., 2010).  Interestingly, the proposed ribose 
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intermediate exists as a glycal, a phenomenon that has not been observed previously in 
nucleoside phosphorylases.  
The structure of bovine PNP (bPNP) is trimeric with molecular weight of 31 
kDa (Mao et al., 1998).  Its primary sequence is 86% identical to that of human PNP.  
Previous work (Ealick et al., 1991) suggested that in the phosphorolytic direction the 
order of binding of phosphate and inosine is random.  The product release step, 
however, is sequential as R1P must be released before hypoxanthine.  In addition, it 
was demonstrated that in the synthetic direction hypoxanthine must bind before R1P 
can bind.  
The lability of the glycosidic bond in aqueous solvent as well as in most 
common organic solvents makes traditional chemical synthesis of nucleoside analogs 
quite challenging.  This is complicated by the necessity of adding and removing 
protecting groups, which lead to very low yields (e.g. 2%).  One way to overcome this 
challenge is to chemically synthesize the modified base and/or modified sugar 
separately and then couple the base and the sugar together enzymatically (Figures 
3.3A, 3.3B).  Therefore, nucleoside phosphorylases can serve as a useful synthetic tool 
for this purpose.  Recent biochemical data (Chapeau & Marnett, 1991) indicate that 
the glycosidic bond of the most abundant by-product of DNA damage, M1G-dR, could 
be generated using Escherichia coli purine nucleoside phosphorylase (EcPNP) by 
coupling the guanine analog, M1G, with the sugar moiety 1 (Figure 3.3A) to give a 
yield of 64%.  However, bPNP cannot couple the same substrates.  Therefore, 
structures of bPNP containing M1G-dR and phosphate or sulfate are needed in order to 
rationalize the observation. 
Here we present two X-ray structures of bPNP in complex with M1G-dR and 
phosphate or sulfate, which was initially thought to be an unreactive mimic of 
phosphate.  A comparison of the structure of EcPNP/inosine/SO4 complex (Bennett et 
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al., 2003) with the structures of the two bPNP complexes suggests that the hydrophilic 
residue Glu201 sterically constrained M1G and induced the glycosidic bond cleavage 
rather than making the glycosidic bond with dR1P.  This structural evidence supports 
our biochemical assay results in which the sugar moiety 1 (Figure 3.3) was 
successfully coupled with M1G using EcPNP but not bPNP.  In addition, we 
unexpectedly observed that the sulfate ion cleaved M1G-dR into a glycal intermediate 
and the M1G base. 
 
 
 
Figure 3.3. Coupling reaction to synthesize purine nucleoside analog catalyzed by 
PNP.  LG of species 1 in panel A represents a leaving group (usually a thymine) and B 
the synthesis reaction where the leaving group is phosphate. 
 
Section 3.2 Experimental 
Synthesis of M1G-dR.  Pyrimidopurinone-2'-deoxyribose was synthesized 
according to the previously published procedures (Schnetz-Boutaud et al., 2000). 
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Protein Purification.  Partially purified purine nucleoside phosphorylase from 
calf spleen was purchased from Sigma Chemical Co.  This protein sample was further 
purified using a reactive dye matrix column.  All steps were performed at 4 °C unless 
otherwise noted.  The Sigma protein was dialyzed against 10 mM MES, pH 6.0 and 1 
mM dithiothreitol (DTT) (loading buffer).  The dialyzed sample was then concentrated 
to a volume of 5 mL, and directly loaded onto a 5 mL green-19 dye matrix column 
pre-equilibrated in loading buffer.  The column was then washed with excessive 
loading buffer until the eluate had no detectable protein concentration.  A two-step 
wash gradient was performed with loading buffer supplemented with 0.4 M and 0.7 M 
NaCl.  The protein was eluted with loading buffer supplemented with 2 M NaCl and 
20 mM ATP.  The eluted protein was dialyzed against 10 mM Tris, pH 7 and 1 mM 
DTT, and concentrated to 8 mg/mL based on a Bradford assay.  
Enzyme Assay.  PNP activity was measured with inosine as substrate (check 
above reference for reference for assay).  Hyphoxanthine formed in the reaction was 
oxidized to uric acid by xanthine oxidase.  The uric acid concentration was monitored 
spectrophotometrically at 293 nm to reflect the amount of PNP product concentration 
With 0.5 mM inosine in 50 mM potassium phosphate buffer at pH 7.5 and xanthine 
oxidase 0.02 µ/mL, 1 unit of PNP activity was defined as the amount of PNP that 
phosphorolyzes 1 µmole of inosine per minute under a temperature of 25 °C.  Specific 
activity is expressed as units per milligram of protein.  
Crystallization.  The purified bovine PNP was crystallized using the hanging 
drop vapor diffusion method at room temperature.  Inhibitors were cocrystallized with 
the enzyme.  The reservoir solution contains 100 mM Tris buffer at pH 7.2-7.6, 10-
12% polyethylene glycol 2000 monomethylether (PEG2000 MME), and 100 mM 
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magnesium acetate with 1 mM potassium phosphate.  Each drop was set up with 2 µL 
of protein solution plus 2 µL of reservoir solution with additional 3mM of inhibitor.  
Crystals appeared from clear drop after about 24 h of equilibrating against the 
reservoir solution, and reached their maximum size over the course of an additional 
few weeks.  
Data Collection.  The X-ray diffraction data were collected at the Cornell High 
Energy Synchrotron Source (CHESS) station F1.  The data were recorded with a 
Quantum 4 mosaic CCD-based X-ray detector made by ADSC.  The detector was 
placed 150 mm from the sample.  The crystals were flash frozen in a gaseous nitrogen 
stream immediately before data collection.  One crystal was used to collect each data 
set.  Each frame was measured with a 1° oscillation angle and a 20 s exposure time.  
53° of 2.4 Å data for the bPNP/M1G-dR/PO4 complex and 60 ° of 2.4 Å data for the 
bPNP/M1G-dR/SO4 complex were collected with nearly 90% completion. 
Data Processing.  X-ray diffraction data were processed using the 
Collaborative Computational Project, Number 4 (CCP4) suite of programs 
(Collaborative Computational Project-Number 4, 1994) Measured intensity were 
converted to structure factors using program TRUNCATE from CCP4. Data collection 
and processing statistics are shown in Table 3.1. 
Structure Determination.  Using a coordinate file of a bovine PNP (4PNP) 
from the protein databank (Federov et al., 2001) as the search model (Berman et al., 
2000), the bPNP complexes were solved by molecular replacement using CNS 
(Brünger et al., 1998), starting with rigid body refinement, simulated annealing, B-
factor refinement, and finally energy minimization.  All the ligands and water 
molecules in the search model were removed.  Several iterative rounds of refinement 
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were performed and alternated by manual model building in COOT (Emsley & 
Cowtan, 2004).  Most of the side chains were adjusted and a few were removed during 
several rounds of refinement.  σA-weighted difference Fourier maps (Read, 1986), 
1Fo-Fc and 2Fo-Fc, as well as composite omit maps were calculated from models 
without ligands after each round of refinement.  Manual model building was done 
using the composite omit map to minimize model bias.   Once the Rfactor and Rfree 
converged, water molecules were added.  The ligands were modelled into the active 
site of each chain of their corresponding bPNP complex.  The ligands were generated 
using PRODRG (Schuettelkopf, 2004).  The geometry of bPNP was validated using 
PROCHECK (Laskowski et al., 1993).  All the figures were produced using PyMOL 
and ChemBioDraw (DeLano, 2002).  The refinement statistics are tabulated in Table 
3.2. 
 45 
Table 3.1. Data Collection Statistics for bPNP Complexes. 
 bPNP/M1G-dR/SO4 bPNP/ M1G-dR/PO4 
source F1 CHESS F1 CHESS 
wavelength (Å) 0.916 0.916 
resolution (Å) 2.4 2.4 
space group P213 P213 
molecules / a.s.u. 1 1 
a (Å) 92.59 92.59 
b (Å) 92.59 92.59 
c (Å) 92.59 92.59 
α (°) 90° 90° 
β (°) 90° 90° 
γ (°) 90° 90° 
unique reflectionsa 9139 9055 
completeness (%) 86.8 (69.1) 89.7 (70.0) 
aValues for the highest-resolution shell are given in parentheses. 
bRsym = ΣΣi | Ii − <Ι> | / Σ <Ι>, where <Ι> is the mean intensity of the N reflections 
with intensities Ii and common indices h,k,l. 
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Table 3.2. Data Refinement Statistics for bPNP Complexes. 
 bPNP/M1G-dR/SO4 bPNP/ M1G-dR/PO4 
resolution (Å) 2.4 2.4 
no. of protein atoms 2199 2177 
no. of ligand atoms 27 27 
no. of water atoms 139 160 
reflections in working set 8620 8820 
reflections in test set 682 690 
R-factora (%) 23.6 23.3 
Rfreeb (%) 27.7 28.3 
rmsd from ideals   
bonds (Å) 0.009 0.008 
angles (°) 1.21 1.13 
avg B factor (Å2) 34.0 13.3 
Ramachandran Plot   
most favored (%) 89.0 89.0 
additionally allowed (%) 11 11 
generously allowed (%) 0.0 0.0 
disallowed (%) 0 0 
aR-factor = Σhkl| |Fobs| − k |Fcal| | / Σhkl |Fobs| where Fobs and Fcal are observed and 
calculated structure factors, respectively. 
bFor Rfree, the sum is extended over a subset of reflections (5%) excluded from all 
stages of refinement.  
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Section 3.3 Results 
Overall Structure. The overall structure of bPNP in complex with ligands 
resembled those previously described (Mao et al., 1998, Luic et al., 2004, Koellner et 
al., 1997, Luic et al., 2001, Toms et al., 2005).  The enzyme is a trimer of three 
identical subunits, each of which has the typical PNP α/β fold containing a central 
mixed eight-stranded β sheet and a smaller five-stranded sheet (Figures 3.4A, B).  The 
twisted β-barrel is flanked on both sides by a total of nine α-helices and two short 310 
helices.  The fold of the bPNP complexes are highly compact with a Matthews number 
of 2.07 corresponding to a solvent content of 40%. 
 
 
 
 
Figure 3.4.  Structures of bPNP.  Panel A contains the biological unit of bPNP and 
panel B contains the monomer found in the asymmetric unit.  The ligands are 
represented by the stick model. 
As seen in Figure 3.4, the active site is located near the monomer-monomer 
interface and buried deeply inside the protein fold.  The active site is divided into three 
parts: the phosphate binding site, the sugar-binding site, and the base-binding site.  
The phosphate-binding pocket is very hydrophilic and contains Ser220, His86, Arg84, 
Hi64, Ala116, and Ser33.  The β face of the sugar moiety interacts hydrophobically 
with M219.  His257 and Tyr88 form hydrogen bonds with O5' and O3' of the sugar 
 48 
respectively.  Both of the phosphate and the sugar binding sites are well conserved 
among the nucleoside phosphorylase I (NP-I) superfamily.  However, the base-binding 
pocket varies within the members of the superfamily.  Residues Thr242, Asn243, 
Val245, Glu201, V217, and Phe200 surround the base region.  Half of these residues 
are hydrophobic and the other half hydrophilic. 
Structure of the bPNP/M1G-dR/PO4 Complex. Figure 3.5 shows the stereo 
diagram of the active site of the bPNP/M1G-dR/PO4 complex.  The phosphate ion 
reacted with M1G-dR to generate M1G and dR1P, both of which are present in the 
active site.  Most of the side chains are well ordered except for a few Lys, Glu, Gln, 
and Arg residues on the surface of the protein.  The electron density from the 
difference map or composite omit map for all the active sites residues as well as for 
the M1G and the phosphate ion are relatively strong.  However, the density for the 
sugar is very weak as is generally the case for these enzymes.  Although the density 
for the sugar is weak, it is clear that the glycosidic bond is broken.  The phosphate ion 
makes hydrogen bonds with Ser220, His86, Arg84, His64, Ala116, and Ser33.  One of 
the oxygen atoms of the phosphate also hydrogen bonds to the 3' OH of the sugar.  
The 2'-deoxyribose makes three hydrogen bonds with His257, Tyr88, and the 
phosphate.  In addition, Met219 interacts hydrophobically with the β face of the sugar 
ring.  Asn243 is still able to make a hydrogen bond with N7 of M1G.  An ordered 
water molecule in the base binding site hydrogen bonds to O6 of the base as well as to 
Glu201.  Another ordered water molecule is present between the phosphate and sugar 
binding sites and makes a hydrogen bond with the sulfate, Ser220.  Phe200 forms a 
herringbone interaction with M1G. 
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Figure 3.5. Stereo view of the active site of bPNP/M1G-dR/PO4 complex, where W 
denotes water (red sphere). 
 Structure of the bPNP/M1G-dR/SO4 Complex. The active site of the 
bPNP/M1G-dR/SO4 complex remains largely unchanged relative to other bPNP 
complexes (Federov et al., 2001, Koellner et al., 1997, Luic et al., 2004, Toms et al., 
2005) as shown in Figure 3.6.  All the residues in the phosphate, sugar, and base 
binding sites did not show any movement beyond expected coordinate errors.  The 
ordered water molecule between the phosphate and sugar binding sites is still present 
but the one in the base binding pocket is not observed.  One unusual observation is the 
appearance of a glycal intermediate in the active site (Figure 3.7).  As mentioned 
previously, the densities for M1G and the sulfate ion were relatively strong but weak 
for the sugar.  The glycosidic bond was not observed in the density.  The structures 
and electron density for M1G, glycal, and the sulfate are shown in Figure 3.7B.  The 
glycal, together with the sulfate, forms the same hydrogen bonding network with some 
of the active site residues as discussed in Figure 3.5. 
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Figure 3.6.  Stereo view of the active site of bPNP/M1G-dR/SO4 complex, where W 
denotes water (red sphere). 
 
 
 
 
Figure 3.7. (A) The formation of the glycal intemediate from the oxocarbenium by 
some base :B.  (B) The bound ligands shown in a composite omit map contoured at 
1.7 σ from bPNP/M1G-dR/SO4 complex. 
 
Section 3.4 Discussion 
Comparison of bPNP/M1G-dR/PO4 and bPNP/M1G-dR/SO4 Complexes. 
Superposition of the active sites of the two complexes is shown in Figure 3.8.  Since 
the two complexes differ only by the identity of the sulfate or phosphate ion, no major 
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conformational change is expected, especially in the active site.  The only observed 
structural difference is a shift in the position of the sugar moiety.  This is due to the 
difference in the outcome of the reaction.  However, the orientation of the sugar 
remains unchanged in general because, in both cases, the sugar moiety interacts 
hydrophobically with Met219.  In both complexes, the same hydrogen bonds are 
observed with His257, Tyr88, and the sulfate ion.  The phosphate actually forms a 
covalent bond with the sugar to become dR1P.  The reason for the weak electron 
density observed for the sugar can be explained by the loss of three hydrogen bonds 
(2' OH) with the sulfate (phosphate), the amide backbone of Met219, and Tyr88 
(Figures 3.10A, B).  Although the hydrophilic residue Glu201 could still hydrogen 
bond to the conserved water observed in the bPNP/M1G-dR/PO4 complex, it lost an 
important hydrogen bond with M1G.  The distance between the Glu201 side chain and 
the closest atoms on M1G fluctuated between 2.6 and 3 Å during different refinement. 
 
 
Figure 3.8. Superposition of the active sites of bPNP/M1G-dR/SO4 (cyan) and 
bPNP/M1G-dR/PO4 (green) complexes, where W denotes water (red sphere).   
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An obviously unfavourable interaction between the charged side chain of the 
Glu201 and M1G is observed in the structure.  This interaction is explained by the 
weak electron density near the edge of M1G (Figure 3.7B).  In fact, the averaged B-
factor for Glu201 side chain is approximately 14 but for M1G it is about 45.  
Nevertheless, adding an extra ring to the natural hypoxanthine base surprisingly did 
not affect the ability of M1G to bind to the active site.  The size of the base does not 
preclude Asn243 from making the critical hydrogen bond to N7 of M1G. 
 The biggest difference between the two bPNP complexes is the observation 
that the sulfate ion unexpectedly cleaved M1G-dR but did not form a covalent bond 
with the sugar.  The bond formation between a sulfate's oxygen and C1´of the sugar is 
not necessarily impossible even though this phenomenon has not been reported in any 
biological transformations.  However, an S-O-C bond does have precedent in 
traditional organic synthesis (Portoghese & Telang, 1971).  In any event, the electron 
density of the difference map as well as the composite omit map do not support the 
existence of the bond between the sulfate and C1´ of the sugar.  As mentioned above, 
the electron density for the sugar, particularly the bPNP/M1G-dR/SO4 complex, is 
weak; however, the geometry of M1G-dR does not fit the observed density.  The 
composite omit map contoured at 1.7 σ  shows the density for the three separate pieces 
(Figure 3.7B).  The possible mechanism for the glycal formation is shown in Figure 
3.7A.  The identity of the base responsible for proton abstraction is not yet known.  
The existence of the glycal intermediate has a precedent in bovine uridine 
phosphorylase from a recent publication (Paul et al., 2010), although the structure of 
that particular glycal is slightly different from one observed here.  In addition, Paul et 
al. observed that the glycal intermediate only formed for uridine, 5-fluouridine, and 5-
fluoro-2'-deoxyribose but not 2'-deoxyribose.  However, as shown in Figure 3.7A, a 
high-energy intermediate like the oxocarbenium has a very short lifetime.  Thus, 
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essentially any base would easily remove one of the hydrogen atoms at C2' to 
spontaneously relieve the positive charge on the O4'.  This brings up the next question 
regarding the identity of the base.  Examining the active site of the complex (Figure 
3.6) reveals that no plausible residues nearby can function as the base.  However, a 
water molecule is present about 4.5 Å away from the sugar.  This water appeared to be 
well ordered by making three hydrogen bonds with Ser220, the sulfate ion, and Tyr88.  
Thus, if the water was to serve as a base, the deprotonation would most likely occur at 
the same time as the active site undergoes conformational change. 
Comparison with the Complex of Escherichia coli PNP/inosine/SO4.  Since 
Escherichia coli PNP (EcPNP) was able to carry out the coupling reaction of M1G 
with a sugar substrate (Figure 3.3), it is necessary to compare the active site of EcPNP 
with that of the bPNP complexes.  Ideally, an active site of EcPNP in complex with 
M1G-dR and SO4 would be best for comparison. However, because the structure of 
this ideal complex is not available the closest structure of EcPNP/inosine/SO4 complex 
(Bennett et al., 2003) is used as shown in Figure 3.9 and Figure 3.10, which is 
redrawn in ChemDraw for comparison with bPNP.  The stereo diagram (Figure 3.9) 
reveals that EcPNP has a Ser203 which hydrogen bonds to Asn204 in the base binding 
pocket which is equivalent to Thr242 and Asn243 of bPNP.  EcPNP also has a 
conserved water hydrogen bonding to the O6 of hypoxanthine, and Ile206, Val178 and 
Phe159 that interact hydrophobically with hypoxanthine, which are equivalent to 
Val245, Val217, and Phe200 in bPNP.  However, EcPNP does not have any 
equivalent of Glu201 in bPNP.  The space presumably occupied by a glutamate 
residue as in bPNP is filled with a few water molecules leading to the widely open 
solvent path.  Thus, EcPNP can easily accommodate at least an extra ring as in M1G 
base.  The presence of the destablizing Glu201-M1G interaction most likely explains 
why EcPNP can couple the reaction of M1G with a sugar moiety (Figure 3.3) to 
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produce M1G-dR analog, whereas bPNP cannot.  The structures of the two bPNP 
complexes also demonstrate that both sulfate and phosphate can cleave the M1G-dR 
though they did not give the exact same products.  Van der Waals repulsion between 
Glu201 and M1G might have facilitated the glycosidic bond cleavage as the active site 
closed up.  The glycal intermediate might have started to form during this time and 
finished by the time the conformational change completed. 
 
 
Figure 3.9. Stereo view of the active site of EcPNP/inosine/SO4 complex reproduced 
from 1PR0 (Bennett et al., 2003), where W denotes water (red sphere). 
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Figure 3.10. ChemDraw® of the active sites of bPNP/M1G-dR/SO4 (B) and 
EcPNP/inosine/SO4 (A) complexes.  Residues with an asterisk come from an adjacent 
monomer.  The ligands are highlighted in red. 
Section 3.5 Conclusion 
The crystal structures of the bPNP/M1G-dR/PO4 and bPNP/M1G-dR/SO4 
complexes were determined at 2.4 Å resolution.  In addition to the observation of the 
glycal intermediate in the bPNP/M1G-dR/SO4 complex, these structures provide useful 
insight to an intriguing question regarding the enzymatic coupling reaction to produce 
M1G-dR, the most abundant by-product of DNA damage in humans at physiological 
pH  (Chaudhary, Nokubo, Marnett et al., 1994, Chaudhary, Nokubo, Reddy et al., 
1994, Leuratti et al., 1998).  For the M1G-dR analog in bPNP, the phosphorolytic 
reaction using a phosphate or a sulfate nucleophile should be spontaneous due to the 
strain-induced facilitation by Glu201 on the M1G base.  However, the synthesis of 
M1G-dR is not possible because of the instability of M1G caused by Glue201 to form a 
glycosidic bond with the sugar moiety.  Thus, EcPNP would be an excellent candidate 
for coupling various nucleoside analogs to study their mutagenic potential in humans. 
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CHAPTER 4  
DESIGN AND SYNTHESIS OF A LIGHT-ACTIVATED INHIBITOR AND 
PRELIMINARY CHARACTERIZATION OFA NOVEL PROTEIN-PROTEIN 
CROSS-LINKED INTERMEDIATE INVOLVED IN THIAMIN 
BIOSYNTHESIS 
Section 4.1 Introduction 
 
Thiamin pyrophosphate (TPP) or thiamin, also known as vitamin B1, is an 
indispensable cofactor in all living systems.  Specifically, it plays a critical role in 
stabilizing acyl carbanion intermediates involved in amino acid and carbohydrate 
metabolism1, 2.  Unlike most prokaryotes and some eukaryotes (plants and fungi), 
humans cannot biosynthesize TPP, and thus need 1.4 mg/day from dietary or 
supplemental sources 3.  In prokaryotes, thiamin is formed by a condensation reaction 
of thiazole and HMP-PP moieties catalyzed by ThiE and ThiL as shown Figure 4.1. 
 
Figure 4.1.  Coupling reaction of two biosynthetic products thiazole and HMP-PP to 
produce thiamin.  
 
The thiazole and HMP-PP moieties themselves are biosynthesized by two 
different biosynthetic pathways.  In Bacillus subtilis, thiazole synthase (ThiG), 
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together with ThiS and three other enzymes (ThiF, ThiO and cysteine desulfurase), 
catalyzes the formation of the thiazole moiety of thiamin using 1-deoxy-D-xylulose-5-
phosphate (DXP), cysteine, and glycine as substrates 4-7 (Figure 4.2).   
 
Figure 4.2.  Biosynthesis of thiazole in B. subtilis. 
 
Recent mechanistic studies 5, 7 suggest that thiazole synthase is covalently 
linked to a sulfur carrier protein (ThiS) by a novel reaction intermediate (4) as shown 
in Figure 4.3.  This is so far the only known intermediate identified that covalently 
links two different proteins.  In this mechanistic proposal, the substrate DXP (1) 
migrates to the active site of ThiG to form an imine linkage with Lys96 and 
tautomerizes to enamine 2, which is further tautomerized to amino-ketone 3.  ThiS 
thiocarboxylate adds to 3 to form intermediate 4, which undergoes an S-O acyl shift to 
give 5.  Dehydration and tautomerization of 5 generates 6.  Elimination of ThiS 
carboxylate from 6 generates 7, which adds to dehydroglycine to form 8.  Species 8 
undergoes transamination to release Lys96 of ThiG and decarboxylation to give 
carboxylated thiazole.  As seen in the mechanistic proposal for the biosynthesis of 
thiazole, all the proposed biochemical transformations occur in the active site of ThiG 
and involve mainly ThiS-ThiG complex.  The other enzymes in this pathway (ThiF, 
 61 
ThiO and cysteine desulfurase) only play a ‘peripheral’ role in modifying ThiS, 
glycine, and cysteine substrates.  
 
 
Figure 4.3.  The formation of the thiazole proceeds via a novel protein-protein 
crosslinking intermediate (4). 
 
The X-ray crystal structure of the ThiS-ThiG complex at 3.2 Å resolution has 
been recently determined 6 (Figure 4.4).  The red ball-and-stick molecule occupying 
the phosphate-binding pocket in the active site is the phosphate ion from the 
crystallization buffer.  This pocket presumably binds to the phosphate group of the 
substrate DXP (1).  
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Figure 4.4.  Stereo view of the ThiS-ThiG complex with ThiS containing secondary 
elements labeled in red and ThiG in black.  The carboxy terminus of ThiS is labeled 
with the red letter C proximal to the phosphate ion, which is shown as the red ball-
and-stick model. 
 
The ThiS-ThiG heterodimer above exists as a tetramer of heterodimers (Figure 
4.5) in solution as measured by dynamic light scattering and size exclusion 
chromatography experiments.  Underlying the static X-ray crystal structure is a 
dynamic binding equilibrium.  The four ThiS monomers bind to the ThiG tetramers 
with an Kon,off rate that translates into a Kd of approximately 70 nM (unpublished data), 
which is a reasonably tight binding.  Nevertheless, the X-ray crystal structure of the 
complex shows that the C-terminus of ThiS in the active site of ThiG is disordered.  
This probably affects the rigidity of the complex, and thus may explain the observed 
low-resolution crystal structure. 
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Figure 4.5.  ThiS-ThiG tetrameric complex at 3.15 Å resolution with ThiS subunits 
labeled as C, C', D, D' and ThiG as A, A', B, B'.  The phosphate ion is shown in ball-
and-stick. 
 
To identify the catalytically important residues, the proposed intermediate 4 
was modeled into the active site.  This modeling revealed that in addition to the Lys96 
involved in imine formation, a Glu98 and an Asp182 are also present in the active site 
(Figure 4.6A). 
 
Figure 4.6.  Comparison of the structure of the ThiS-ThiG crosslinking intermediate 
(A) with that of the proposed analog (B). 
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Since the complex was solved at a relatively low resolution without any bound 
ligand and the functions of Glu98 and Asp182 remain ambiguous by mutagenesis 
studies, the focus of this project is to synthesize an analog of the putative intermediate 
4, and to solve the X-ray crystal structure of the analog complex.  The analog complex 
is anticipated to give higher resolution crystals, because the flexible carboxy terminus 
of ThiS-COOH will be anchored at the active site. 
The proposed analog is shown in Figure 4.B.  This analog is similar to the 
intermediate 4 (Figure 4.3 or Figure 4.6A) with the following differences.  1) ThiS is 
linked to the analog via a stable amide bond as opposed to the thioester bond of the 
intermediate.  2) The thiol group at C4 of the analog replaces the hydroxyl group at C4 
of the intermediate.  3) The phosphate-binding pocket of the analog will be occupied 
by a phosphate ion presumably from the crystallization buffer. 
Section 4.2 Results and Discussion 
 
The strategy for making the analog 4 (Figure 4.6B) is shown in Figure 4.7.  The 
thiol moiety of cysteine (9), being a powerful nucleophile as well as a strong oxidizer, 
needs to be protected to form species 10.  The amino group is next protected with a 
compatible protecting group to produce 11.  The carboxylic acid is then stepwise 
converted to a methyl ketone 12.  The carbonyl oxygen is finally protected with an 
appropriate protecting group.  Now the amino group is deprotected first to generate 
species 14.  Then the thiol moiety is deprotected in order to carry out intein chemistry8 
in the next step.  Chemical ligation using intein chemistry gives 16.  After an S-to-N 
acyl shift, a more thermodynamically stable species 17 is generated.  The carbonyl 
oxygen is finally deprotected to free up the methyl ketone moiety as shown as 18, 
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which is inserted into the active site of ThiG to form a Schiff base linkage with Lys96 
of ThiG as in 19. Following reduction of 19, a stable N-C bond of species 20 is 
formed. 
 
Figure 4.7.  Strategy for making analog 4, where ‘PG’ represents a protecting group. 
 
The intein chemistry employed in one of the steps above is, in general, a 
powerful way to ligate together different protein segments, or a protein and a small 
cysteine-like molecule containing a sulfhydryl and an amino groups that are three 
bonds apart, to generate a fully functional protein in a process known as protein 
semisynthesis (Figure 4.8).  This technique is very useful for producing a large 
quantity of proteins that are difficult to express by conventional biochemical methods.  
More specifically for this particular system, ThiS is attached to an intein construct that 
contains a chitin binding domain (CBD, 21), which undergoes an equilibrium N-S acyl 
shift.  The resulting adduct 22 undergoes 2-mercaptoethanesulfonic acid (MESNA)-
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induced cleavage from the CBD column to give a thioester intermediate 23.  A 
neighboring thiol group of a cysteine on ThiS participates in the formation of the 
cyclic intermediate 24 by attacking 23 to displace the MESNA from ThiS.  The cyclic 
species 24 then can react with any amino-thiol containing compounds to form the 
ligated ThiS. 
 
Figure 4.8.  Intein chemistry to ligate ThiS to a cysteine-like molecule containing a 
sulfhydryl and an amino groups that are three bonds apart; CBD stands for chitin 
binding domain. 
 
As indicated above, the analog must have the amino-thiol functionality for 
intein chemistry to work.  In addition, it has to contain a methyl ketone in order to 
form an imine bond with Lys96 of ThiG in the active site.  Thus, the general strategy 
for making the proposed analog is shown in Figure 4.9.  Accordingly, the amino-thiol-
ketone 25 is ligated to ThiS by intein chemistry.  Following rearrangement via 26, the 
ligated adduct 27 is reacted with ThiG to form 28, and finally the proposed analog 4 
after sodium borohydride reduction. 
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Figure 4.9.  Design of the proposed analog 4. 
 
The chemical synthesis of the amino-ketone 25 is shown in Figure 4.10.  The 
thiol moiety of cysteine (9) is protected with the tert-butyl group under acidic 
conditions to form 30.  The amino group is next protected with Boc2O under basic 
conditions to produce 31.  The carboxylic acid is then converted to Weinreb’s 9 amide 
32 using 1-(3-dimethylaminopropyl)-3-ethyl carbodiimide hydrochloride (EDCI) as an 
activator, and 4-dimethylaminopyridine (DMAP) and hydroxybenzotriamole (HOBt) 
as catalytic nucleophiles.  Finally, the tert-butyl group is removed with mercuric 
acetate in trifluoroacetic acid to afford 25. 
Compound 25 was synthesized, but intein chemistry could not be carried out 
because the molecule is very unstable and degraded at neutral and basic pHs.  Intein 
chemistry requires a pH of 7 or higher. 
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Figure 4.10.  Chemical synthesis of proposed amino-ketone 25. 
 
Thus, one solution to this problem is to find a way to synthesize an analog 
containing the amino-thiol functionality and a protected methyl ketone.  This thinking 
led to the modified strategy is shown in Figure 4.11.  One modification in the strategy 
is that the ketone protecting group in shown in 34, 35, and 36 somehow must be 
removed before insertion into the active site of ThiG. 
 
Figure 4.11.  Modified strategy to make the proposed analog 4 with a protecting group 
(PG) on the ketone. 
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Since any protecting group used must be compatible with intein chemistry, the 
choices are severely limited—no acids, bases, nor oxidizing/reducing reagents.  The 
most logical protecting group is the photolyzable nitrophenyl ethylene glycol as shown 
below. 
 
Unfortunately, this compound is quite expensive for initial trial reactions; thus, 
ethylene glycol was used as a model protecting group while a workable synthetic route 
as well as intein chemistry was designed, before using the photolyzable protecting 
group.  The synthetic scheme for model analog 37 to generate 39 via 38 is shown in 
Figure 4.12 and the actual synthesis is presented in Figure 4.13. 
 
Figure 4.12.  Model analog 37 for a workable synthetic route and intein chemistry. 
 
The first three steps to generate 32 are the same as before (Figure 10).  In the 
next step, the Boc protecting group is replaced with trifluoroacetamide to give 41 via 
40 because Boc interferes with the protection of the ketone with ethylene glycol in a 
later step.  Next, the Weinreb’s amide is converted to ketone 42 by a Grignard’s 
reaction.  The trifluoroacetamide protecting group on the amine is simultaneously 
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removed with excess Grignard’s reagent.  The ketone moiety is then protected as an 
acetal (43) using ethylene glycol.  Finally, the tert-butyl group is removed with 
mercuric acetate to afford 37.   
 
Figure 4. 13.  Synthetic route for the model analog 37. 
 
The synthesis was completed and a very good yield of 37 was obtained.  
Compound 37, together with two other amino-ketone compounds, was ligated to ThiS 
to demonstrate the proof-of-concept for intein chemistry as shown in Figure 4.14.  The 
2-aminoethanethiol (46) is commercially available and is used as a control.  
Compound 44, a close version of the proposed analog, was synthesized similarly to 
that of 37 (see Experimental Section).  Compounds 37, 44, and 46 were ligated to 
ThiS (the cyclic intermediate is shown) to generate 39, 45, and 47.  The deconvoluted 
Electrospray Ionization Mass Spectrometry (ESI-MS) spectra for the cyclic ThiS (24) 
and one of the ligated ThiS adducts (39) are shown in Figures 4.15A and 4.15B.  The 
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resolution of the ESI-MS is approximately one Dalton.  Figure 4.15A shows the mass 
spectrum of the cyclic ThiS (24) with a molecular weight of 7609 Da for the expected 
molecular weight of 7607 Da.  The expected molecular weight of 39 is 7770 Da and 
the mass spectrum in Figure 4.15B recorded a value of 7771 Da. 
 
Figure 4.14.  Intein chemistry to add amines to the C-terminus of ThiS-COOH. 
  
In order to ascertain that the robustness of this ligation, compound 44 was 
synthesized and adduct 45 was made.  The FT-MS for adduct 45 with the exact 
molecular weight of 7727 is shown in Figure 4.15C.  These experiments turned out to 
be very robust and were measured repeatedly many times to ascertain the identity of 
the ligated adducts.  Compound 45 was purchased from Sigma-Aldrich and used to 
generate 47.  The ESI-MS data for 47 was also taken to confirm successful ligation 
(data not shown). 
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Figure 4.15.  Deconvoluted ESI-MS spectra of the cyclic ThiS (24) in panel A and a 
ligated ThiS (39) in panel B.  Panel C shows the FT-MS spectrum for adduct 45.  The 
peak at 7625 is the hydrolyzed product of the cyclic ThiS (24) or ThiS-COOH. 
 
Since the synthesis and intein chemistry worked for the model analog 37, the 
photolyzable analog 49 with nitrophenyl ethylene glycol protecting group was 
similarly synthesized as shown in Figure 4.16.  The yield for 49 is not as high as 37 
but sufficient for our purpose. 
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Figure 4.16.  Synthesis of the photolyzable analog 49. 
 
The synthesized compound 49 was shown to be photolyzable in either 
methanol or water using 48 instead of 49 for simplicity (Figure 4.17).  The deprotected 
compound 42 was formed in one hour as confirmed by NMR. 
 
Figure 4.17.  Model reaction for photo-deprotection. 
 
Another unanticipated problem arose regarding the solubility of 49.  It was not 
soluble in 30 mM Tris buffer (pH 7.5), which is the buffer used for ThiS, and it 
precipitated out of the solution even with low level (2-10%) of organic solvents such 
as dimethyl formamide or dimethyl sulfoxide (Figure 4.18). 
 
Figure 4.18.  Intein chemistry to ligate 49 to ThiS. 
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To increase solubility, a hydrophilic functional group was put on 49.   
Specifically, a carboxylic group was installed on the carbon of the primary diol as 
shown in Figure 4.19 (compound 54).  The nitrobenzaldehyde 51 undergoes a Wittig 
reaction to form alkene 52, which is dihydroxylated to produce 53.  Ester hydrolysis of 
53, which is passed through the cation exchanged to give 54. 
 
Figure 4.19.  Synthesis of the modified photolyzable analog 54. 
 
Compounds 53 and 54 were then used to protect ketone 42 (Figure 4.20).  
However, both reactions failed because the ethyl group in 53 interfered with the 
protection step and compound 54 is not soluble in benzene. 
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Figure 4.20.  Protection of ketone 42 using 53 and 54. 
 
Therefore, several photolyzable analogs (57, 58, 59) with soluble functional 
groups added were proposed as shown in Figure 4.21.  Compound 59 is most suitable 
for the intended purpose because ether linkage on the benzene ring is known to have 
no affect on the photodeprotection step.  Its synthesis is shown in Figure 4.22. 
 
Figure 4.21.  Proposed photolyzable analogs containing an additional soluble group. 
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Figure 4.22.  Synthesis of the photolyzable analog 59. 
 
The commercially available 5-hydroxy-2-nitrobenzaldehyde (60) is reacted 
with methyl bromoacetate in tetrahydrofuran to form 61.  The addition of the Wittig’s 
reagent, methyl triphenyl phosphonium chloride, to 61 gives alkene 62, which is 
dihydroxylated by osmium tetroxide to form 63.  The aminoketone 42, which is 
synthesized as described in Figure 4.13, is protected as a photo-removable acetal 64 by 
a reaction with 63 under reflux condition.  Compound 64 undergoes ester hydrolysis 
followed by cation exchange with Dowex-50W resin to give 65.  Finally, the tert-butyl 
group is removed by mercuric acetate in trifluoroacetic acid to afford the final product 
59. The synthesis for compound 59 was achieved with a good overall yield.  Ellman 
reagent’s assay 10 (Figure 4.23) was carried out to determine the concentration of the 
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free thiol of 59 using cysteine for the standard curve.  Ellman's reagent 66 reacted with 
59 to generate a disulfide 67 and 68, which has the absorbance of visible light at 412 
nm with an extinction coefficient of 14, 150 M-1 cm-1 11.  The free thiol groups tend to 
form disulfide bonds relatively easily and thus may underestimate the actual 
concentration of 59.  Nevertheless, the concentration of 59 was estimated to be at least 
6 mM by this assay. 
 
Figure 4.23.  Ellman's assay for free thiol concentration. 
 
Section 4.3 Conclusion 
 
We have synthesized the analog in relatively good yield based on Ellman's assay 
and also demonstrated the proof-of-concept to covalently link an aminothiol ligand to 
ThiS using intein chemistry.  In particular, we have shown that ThiS can be covalently 
linked to 37, 44, and 46 to give 39, 45, and 47, respectively, and confirmed the 
resulting covalent adducts using ESI-MS and FT-MS.  The objective of future studies 
is to attach 59 to ThiS using intein chemistry to generate 69 (Figure 4.24).  Photolysis 
of 69 using Hanovia lamp in the presence of ThiG should regenerate methyl ketone 27 
and facilitate the Schiff base linkage with Lys96 of ThiG to produce 28.  Sodium 
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borohydride reduction of 28 will trap the proposed analog 4, which will be confirmed 
by SDS PAGE, FT-MS, and X-ray crystallography. 
 
Figure 4.24.  Reactions to covalently link ThiS-59 adduct (69) to ThiG. 
Section 4.4 Experimental Section 
 
Mass Spectrometry. The molecular weight of small molecules and proteins 
were determined by an electrospray ioninzation mass spectrometer (ESI-MS) with a 
hybrid triple quadrupol/linear ion trap 4000 Q trap (Applied Biosystems/MDS Sciex).  
All samples were purified and resuspended in acetonitrile/water solvent system 
containing 0.1% of trifluoroacetic acid.  Some of the protein samples were analyzed 
by FT-MS in collaboration with Professor Fred McLafferty's group. 
Intein Chemistry to Ligate ThiS to Amino-Thiol Compounds. All the reagents 
in these procedures and subsequent synthesis were purchased from Sigma-Aldrich (St. 
Louis, MO), except that the chitin beads were purchased from New England BioLabs 
(Ipswich, MA).  Unless noticed otherwise, all reactions were carried out at room 
temperature.  The procedures are as follows.  Two cell pellets of ThiS-chitin binding 
domain construct from 2 L cell culture, were resuspended in 50 mL cold lysis buffer 
(20 mM Tris pH 7.5, 500 mM NaCl, 1 mM EDTA, 0.1% (v/v) TritonX-100).  The 
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suspension was lysed by sonication on ice.  The lysate was centrifuged at 38, 000 g for 
30 minutes to clarify.  In the meantime, the chitin column was regenerated by soaking 
it with 0.3 M NaOH and then washing with 20 bed volumes of water followed by 5 
bed volumes of column buffer (20 mM Tris pH 7.5, 500 mM NaCl, 1 mM EDTA).  
The clarified cell lysate was loaded on the column and was allowed to flow at a low 
rate (~1 mL/min).  Then the column was washed with 20 bed volumes of column 
buffer.  Finally column buffer containing 60 mM sodium 2-mercaptoethanesulphonate 
(MESNA) was loaded (3 x bed volume) and the column was allowed to sit for 20 
hours at room temperature (20°C).  After 20 hours the column was eluted with 20 mL 
of column buffer and was immediately desalted into 20 mM of Tris pH 7.0.  The 
eluted protein or cyclic ThiS (24)  was concentrated to 500 µL. To 150 µL of the 
concentrated protein an amino-thiol compound was added to get a final concentration 
of 10 mM.  The mixture was incubated for 10 minutes and was immediately desalted 
to 20 mM of Tris pH 7.0 containing sodium azide.  The sample was analyzed by ESI-
MS. 
Synthesis of Compound 25.  To 1.45 mmol of 33 in a 100 mL round-bottomed 
flask, 1.45 mmol of TFA and 0.790 mL or 7.25 mmol of anisole were added.  The 
reaction mixture was cooled to 0º C before adding 1.45 mmol of Hg(Oac)2.  The 
reaction mixture was stirred for 30 min.  Then, H2S was bubbling in very slowly for 2 
minutes until black precipitate (HgS) was formed.  The whole reaction mixture was 
filtered through a celite bed and rinsed with 50% MeOH/TFA.  The final mixture 
containing 25 was rotavaped and put on a vacuum overnight.  Species 25 turned out to 
be unstable at neutral and basic pH.  Thus, it was not purified and no NMR data were 
taken for this product. 
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Synthesis of Compound 30. In a 100 mL round-bottomed flask, 5 g cysteine, 5 
mL of tBuOH, and 17 mL of 3 M HCl (36.6 g/mol) were added.  The reaction mixture 
was refluxed overnight at 85°C.  Thin layer chromatography (TLC) with Ninhydrin 
staining was carried out to monitor the reaction.  The precipitate crystallized out and 
was collected by filtration with a Buchner funnel.  The crystals was washed with ethyl 
ether and vacuum-dried.  30: 1H NMR (300 MHz, D2O) δ 4.06 (m, 1H), 2.95 (m, 1H), 
1.15 (s, 9H). 
Synthesis of Compound 31. In a 100 mL round-bottomed flask, 2 g of 30, 20 
mL of MeOH (anhydrous), 2.6 g of Boc2O and 26.6 mmole of Et3N was added.   The 
whole reaction mixture was stirred for 3 hours at room temperature.  TLC with ceric 
ammonium molybdate (CAM) was carried out to monitor the reaction progress.  A 
milky semisolid product was extracted with CH2Cl2, saturated NH4Cl, saturated 
NaHCO3, and finally saturated NaCl.  Then, it was dried over MgSO4 and rotavaped to 
dryness.  31: 1H NMR (300 MHz, CDCl3) δ 5.35 (s, NH), 4.52 (m, 1H), 3.01 (m, 1H), 
3.48 (s, 1H), 1.30 (s, 9H), 1.43 (s, 9H). 
Synthesis of Compound 32. The yield from 31 above was stirred in a 100 mL 
round-bottomed flask and flushed with argon.  25 mL of anhydrous CH2Cl2 was 
added.  The flask was transferred to a NaCl-containing -12°C ice bath and 4 mmol of 
DMAP were added.  Five minutes later, 4 mmol of EDCD.HCl were added.  After 
twenty minutes later, 4 mmol of HOBt and 4 mmol of Weinreb’s amide, 
NHMe(OMe), were added simultaneously.  The reaction mixture was allowed to react 
for about 2-3 hours.  The reaction mixture was extracted with CH2Cl2, 1 M HCl, 
saturated NH4Cl, saturated NaHCO3, and finally saturated NaCl.  Then, it was dried 
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over MgSO4 and rotavaped to dryness.  32: 1H NMR (300 MHz, CDCl3) δ 5.32 (s, 
NH), 4.84 (m, 1H), 3.22 (s, 3H), 3.78 (s, 3H), 2.88 (m, 1H), 1.30 (s, 9H), 1.42 (s, 9H). 
Synthesis of Compound 33. 2.2 mmol of 32 dissolved in 12 mL of ethyl ether 
was cooled to 0º C.  24 mmol of The Grignard reagent, MeMgBr, was added dropwise 
over 10 min.  The reaction mixture was allowed to run for 2 hours.  Then, saturated 
NH4Cl was added to quench MeMgBr until white precipitate of Mg(OH)2 was 
observed to form.  The liquid portion was extracted with CH2Cl2, saturated NH4Cl, 
saturated NaHCO3, and finally saturated NaCl.  Then, it was dried over MgSO4 and 
rotavaped to dryness.  33: 1H NMR (300 MHz, CDCl3) δ 5.50 (s, NH), 2.10 (s, 3H), 
4.73 (m, 1H), 2.81 (m, 1H), 2.95 (m, 1H), 1.33 (s, 9H), 1.42 (s, 9H). 
Synthesis of Compound 37. In a 50 mL round-bottomed flask, the purified 
species 43 was added with 10 mL of 98% pure TFA and 9 mmol of anisole.  The 
reaction mixture was cooled to 0°C before 2.2 mmol of Hg(OAc)2 was added.  The 
mixture was allowed to stir for 2 hours and then was rotavaped to complete dryness in 
15 minutes to remove all the TFA.  The dry solid was re-dissolved in ether and H2S 
was bubbling in very slowly for 1 minute until black precipitate was formed.  The 
whole reaction was filtered through a celite bed and washed with ethyl ether.  The 
filtrate was rotavaped again for 15-20 minutes and 43 was purified by column 
chromatography with 5% MeOH/chloroform.  43: 1H NMR (300 MHz, CDCl3) δ 6.75 
(m, NH2), 1.32 (s, 3H), 2.95 (m, 1H), 3.45 (m, 1H), 3.53 (m, 1H), 3.95 (m, 2H), 4.05 
(m, 2H). 
Synthesis of Compound 40.  To the starting material 32 (2.2 mmol) in a 50-mL 
round-bottomed flask 3 mL of 98% pure TFA were added.  The whole mixture was 
allowed to react for 2 hours at 0°C.  The product was rotavaped for 20 minutes to get 
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rid some of TFA was extracted with CH2Cl2, saturated NH4Cl, saturated NaHCO3, and 
finally saturated NaCl.  Then, it was dried over MgSO4 and rotavaped to dryness.  40: 
1H NMR (300 MHz, CDCl3) δ 6.75 (m, NH2), 3.67 (s, 3H), 2.71 (s, 3H), 3.53 (m, 1H), 
3.05 (m, 1H), 3.45 (m, 1H), 1.25 (s, 9H). 
Synthesis of Compound 41. To the starting material 40 (8 mmol) in a 50 mL 
round-bottomed flask 15 mL of anhydrous dichloromethane was added.  Then 25 
mmol of triethylamine was added and followed by 7.1 mmol of TFAA.  The whole 
mixture was allowed to react with stirring at 0°C for 2 hours and then room 
temperature.  The reaction mixture turned yellow after 0.5 hours.  The product was 
extracted with saturated NH4Cl, saturated NaHCO3, and finally saturated NaCl.  Then, 
it was dried over MgSO4 and rotavaped to dryness.  This reaction gave a high yield if 
left overnight.  41: 1H NMR (300 MHz, CDCl3) δ 5.50 (s, NH), 3.67 (s, 3H), 2.71 (s, 
3H), 4.81 (m, 1H), 3.12 (m, 1H), 2.95 (m, 1H), 1.33 (s, 9H). 
Synthesis of Compound 42. To the starting material 41 (2.2 mmol), 12 mL of 
dry ether was added drop-wise to a 100 mL round-bottomed flask containing excess 
MeMgBr in ice (0ºC).  The reaction mixture was allowed to run for 2 hours.  20 mL of 
saturated NH4Cl was added to quench MeMgBr.  The liquid portion was extracted 
with CH2Cl2, saturated NH4Cl, saturated NaHCO3, and finally saturated NaCl.  Then, 
it was dried over MgSO4 and rotavaped to dryness.  42: 1H NMR (300 MHz, CDCl3) δ 
6.75 (m, NH2), 1.32 (s, 3H), 3.53 (m, 1H), 3.05 (m, 1H), 3.45 (m, 1H), 1.33 (s, 9H). 
Synthesis of Compound 43. The starting material 42 (2 mmol) in a 100 mL 
round-bottomed flask containing 20 mL of benzene was stirred for a few minutes.  0.6 
mmol of p-TsOH and excess of ethylene glycol were added to the flask.  The reaction 
mixture was refluxed for 3 hours at 95ºC.  The product was purified by flash column 
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with 1.25% methanol/chloroform solvent mixture.  43: 1H NMR (300 MHz, CDCl3) δ 
6.75 (m, NH2), 2.10 (s, 3H), 1.33 (s, 9H), 3.53 (m, 1H), 3.05 (m, 1H), 3.45 (m, 1H), 
3.95 (m, 1H), 4.05 (m, 1H), 4.16 (m, 1H), 4.26 (m, 1H). 
Synthesis of Compound 44. This compound was synthesized using the same 
synthetic route as shown in Figure 4.10 with two exceptions.  First, in the 3rd step 
Weinreb's reagent is replaced with ammonia.  Second, the 4th step is skipped and 
excess of TFA was used in the last step.  44: 1H NMR (300 MHz, D2O) δ 4.13 (s, 1H), 
3.32 (m, 2H). 
Synthesis of Compound 48.  The procedures are the same as those of 43. 48: 1H 
NMR (300 MHz, CDCl3) δ 1.40 (s, 3H), 6.75 (m, NH2), 5.75 (m, 1H), 2.95 (m, 1H), 
3.12 (m, 1H), 1.12 (s, 9H), 3.65 (m, 2H), 4.75 (m, 2H), 7.50 (m, 2H), 7.81 (m, 1H), 
8.18 (m, 1H). 
Synthesis of Compound 49.  The procedures are the same as those of 37.  49: 
1H NMR (300 MHz, CDCl3) δ 1.40 (s, 3H), 6.60 (m, NH2), 5.75 (m, 1H), 2.85 (m, 
2H), 3.71 (m, 2H), 4.61 (t, 1H), 7.52 (m, 2H), 7.91 (m, 1H), 8.13 (d, 1H). 
Synthesis of Compound 52.  In a 100 mL round-bottomed flask, 2 mmol of 51 
and 1.5 mmol of Ph3P=CHCOOEt were added.  The mixture was refluxed in toluene 
for 3 hours.  The adduct was then rotavaped and 52 was purified by column 
chromatography using 1.25% MeOH/CHCl3 solvent mixture.  52: 1H NMR (300 MHz, 
CDCl3) δ 1.36 (t, 3H), 4.29 (q, 2H), 8.36 (d, 1H), 6.38 (d, 1H), 8.00 (d, 1H), 7.79 (m, 
1H), 7.89 (m, 1H), 8.21 (d, 1H).   
Synthesis of Compound 53.  2 mmol of 52, 5 mol% of OsO4 and 1equivalent of 
NMO were mixed together in a 100 mL round-bottomed flask containing t-BuOH 
solvent.  The reaction mixture ran for 2 hours, after which 53 was purified by column 
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chromatography using 5% MeOH/chloroform solvent mixture.  53: 1H NMR (300 
MHz, CDCl3) δ 7.64 (m, 1H), 8.01 (d, 1H), 7.77 (m, 1H), 7.62 (d, 1H), 5.22 (d, 1H), 
4.52 (d, 1H), 3.65 (s, OH), 2.85 (s, OH), 4.21 (q, 2H), 1.29 (t, 3H). 
Synthesis of Compound 54.  1.5 mmol of 53 was reacted with excess amount of 
NaOH in a 50 mL round-bottomed flask containing MeOH solvent.  The reaction 
proceeded from 1 hour and 54 was purified by t-BuOH-AcOH-H2O (2:1:1, v/v) 
solvent system.  54: 1H NMR (300 MHz, CDCl3) δ 7.64 (m, 1H), 8.21 (d, 1H), 7.77 
(m, 1H), 7.62 (d, 1H), 4.91 (d, 1H), 4.56 (d, 1H), 3.65 (s, 1H), 2.85 (s, 1H). 
Synthesis of Compound 59.  The procedures are the same as those of 37. 59: 1H 
NMR (300 MHz, CDCl3) δ 4.66 (s, 2H), 7.18 (d, 1H), 8.08 (d, 1H), 7.40 (s, 1H), 5.18 
(m, 1H), 4.07 (m, 1H), 4.32 (m, 1H), 1.32 (s, 3H), 5.11 (d, NH2), 3.53 (m, 1H), 2.90 
(m, 1H), 2.65 (m, 1H). 
Synthesis of Compound 61.  2.2 mmol of the commercially available 60 was 
dissolved in THF solvent in a 100 mL round-bottomed flask.  One equivalent of NaH 
was added and allowed to run for about 1 hour.  Then, 3 mmol of methyl 2-
bromoacetate was added and the mixture was let to react for 3 hours.  The product was 
filtered with Whatman paper and purified by column chromatography using 2.5% 
MeOH/chloroform solvent mixture. 61: 1H NMR (300 MHz, CDCl3) δ 3.68 (s, 3H), 
4.96 (s, 2H), 7.70 (s, 1H), 7.53 (d, 1H), 8.34 (d, 1H), 11.0 (s, 1H). 
Synthesis of Compound 62.  In a 100 mL round-bottomed flask, THF solvent 
was chilled to -78°C with dry ice.  2 mmol of the starting material 61 was added first 
to the flask.  Then 4 mmol of Ph3P=CH2 was added and followed by 4 mmol of 
LiHMDS.  The reaction ran for 3 hours and the product was purified by column 
chromatography using 2.5% MeOH/CHCl3 solvent mixture.  The yield for this 
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reaction is generally low, 10-25%.  62: 1H NMR (300 MHz, CDCl3) δ 3.68 (s, 3H), 
4.96 (s, 2H), 7.19 (s, 1H), 7.33 (d, 1H), 8.10 (d, 1H), 5.45 (m, 1H), 5.68 (m, 1H), 7.19 
(m, 1H). 
Synthesis of Compound 63.  This dihydroxylation is a variation of 
Barry/Sharpless's procedure.  2 mmol of 62 was mixed with 5% mol of OsO4, 1.1 
equivalents of NMO in t-BuOH solvent.  The reaction ran for about 5 hours and the 
adduct was filtered with Whatman paper.  The filtrate was purified by column 
chromatography using 10% MeOH/CHCl3 solvent mixture.  63: 1H NMR (300 MHz, 
CDCl3) δ 3.68 (s, 3H), 4.96 (s, 2H), 7.40 (s, 1H), 7.18 (d, 1H), 8.08 (d, 1H), 4.59 (t, 
1H), 3.88 (m, 1H), 4.13 (m, 1H), 3.65 (s, OH). 
Synthesis of Compound 64.  The procedures are the same as those of 43. 64: 1H 
NMR (300 MHz, CDCl3) δ 3.68 (s, 3H), 4.96 (s, 2H), 7.18 (d, 1H), 8.08 (d, 1H), 7.40 
(s, 1H), 5.18 (m, 1H), 4.07 (m, 1H), 4.32 (m, 1H), 1.32 (s, 3H), 5.11 (d, NH2), 3.53 
(m, 1H), 2.79 (m, 1H), 2.54 (m, 1H), 1.33 (s, 9H). 
Synthesis of compound 65.  The procedures are the same as those of 54. 65: 1H 
NMR (300 MHz, CDCl3) δ 4.66 (s, 2H), 7.18 (d, 1H), 8.08 (d, 1H), 7.40 (s, 1H), 5.18 
(m, 1H), 4.07 (m, 1H), 4.32 (m, 1H), 1.32 (s, 3H), 5.11 (d, NH2), 3.53 (m, 1H), 2.79 
(m, 1H), 2.54 (m, 1H), 1.33 (s, 9H). 
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CHAPTER 5  
PRELIMINARY CRYSTALLOGRAPHIC STUDIES OF ENZYMES IN THE 
METHIONINE BIOSYNTHETIC AND SULFUR ASSIMILATION 
PATHWAYS OF WOLINELLA SUCCINOGENES 
Section 5.1 Introduction 
 
One way proteins carry out sulfur transfer is via the sulfate assimilation 
pathway (Figure 5.1), in which a sulfate ion is somehow incorporated into adenosine 
monophosphate (AMP) at the 3' hydroxyl groups of the phosphate to form adenosine-
5'-phosphosulfate (APS).  APS kinase phosphorylates the 3' hydroxyl group of APS to 
produce 3'-phosphoadenosine-5'-phosphosulfate (PAPS).  PAPS reductase, a 
thioredoxin-dependent protein, reduces PAPS to sulfite, which is taken up by 
ferridoxin sulfite reductase (FSR) to produce sulfide for incorporation into other 
proteins or amino acids such as cysteine and methionine.  However, the mechanism of 
sulfur incorporation remains unknown.  A BLAST (Altschul et al., 1997) search for 
the superfamily of sulfur carrier proteins in the protein data base SEED identifies a 
gene cluster containing genes for proteins in the sulfate assimilation pathway, a sulfur 
carrier protein, as well as proteins in the methionine biosynthetic pathway of Wolinella 
succinogenes.  This empirical observation has led us to hypothesize that the sulfur of 
methionine originates from the sulfate in the sulfate assimilation pathway. As shown 
in Figure 5.1, the sulfide generated from the sulfate assimilation pathway is 
hypothesized to transfer to the adenylated HcyS (a ThiS-like protein in B. subtilis), 
which has undergone a one-residue C-terminal cleavage from the full-length HcyS by 
some protein and adenylation by another protein.  The gene cluster also contains, 
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among other unidentified proteins, ThiF-like protein (HcyF), QbsD-like protein 
(HcyD), and O-acetylhomoserine sulfhydrylase (MetY) protein. 
 
 
Figure 5.1.  Putative sulfur source for methionine biosynthesis in Wolinella 
succinogenes with the full-length sulfur carrier protein HcyS-Gly-Gly-Ala.  The 
transferred sulfur is labeled in red. 
 
In Escherichia coli or Bacillus subtilis, ThiS was shown to be the sulfur carrier 
protein (Dorrestein et al., 2004, Settembre et al.).  QbsD from Psuedomonas 
fluoescens has been characterized recently (Godert et al.), although its structure has 
not been determined.  It is a putative metal-dependent hydrolase with a JAMM motif 
(Burns et al., 2005) based on a BLAST search (Altschul et al., 1997).  Thus, HcyD 
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probably cleaves the last terminal alanine of HcyS.  The truncation exposes the gly-gly 
residue, which is the carboxy terminal signature motif for a family of sulfur carrier 
proteins like ubiquitin, MoeD, CysO, and ThiS (Godert et al.).  After the truncation, 
the carboxy terminus of HcyS inserts into the active site of HcyF for activation or 
adenylation.  Escherichia coli ThiF (EcThiF) is known to use ATP to activate EcThiS 
by adenylating its C-terminal carboxylic group, and thus turning it into a better leaving 
group (Duda et al.).  Therefore, HcyF perhaps performs the same function as EcThiF 
by adenylating HcyS. The activated HcyS would then undergo further transformations 
to transfer sulfur to other substrates.   
It is also known that the incorporation of sulfur into Bacillus subtilis ThiS is 
generally carried out by the enzyme cysteine desulfurase to generate ThiS 
thiocarboxylate (Dorrestein et al., 2004).  Cysteine desulfurase does not exist in this 
gene cluster.  However, MetY is another protein found in this gene cluster.  MetY 
belongs to the family of O-acetylserine sulfhydrylases, which are known to convert O-
acetylserine to cysteine using a sulfide.  Accordingly, MetY should convert O-
acetylhomoserine to homocysteine using a sulfide.  Alternatively, MetY in this gene 
cluster might participate in sulfur transfer from HcyS thiocarboxylate to generate 
homocysteine.  The objective of this project is to obtain crystal structures of key 
proteins and protein complexes in order to shed light on the mechanism of sulfur 
transfer in Wolinella succinogenes. 
Section 5.2 Materials and Methods 
 
Molecular Cloning.  Standard methods were used for DNA manipulations 
(Sambrook et al., 1989, Ausubel & Brent, 1987).  Plasmid DNA was purified with the 
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Fermentas GeneJet miniprep kit and DNA fragments were purified from agarose gel 
with the Zymoclean Gel DNA Recovery kit from Zymo Research.  The E. coli strain 
MachI (Invitrogen) was used as a recipient for transformations during plasmid 
construction and for plasmid propagation and storage.  Phusion DNA polymerase 
(New England Biolabs) was used for PCR following the manufacturer’s instructions.  
The plasmid THT is a derivative of pET-28, which was obtained from Novagen.  
Genomic DNA from Wolinella succinogenes FDC 602W (ATCC catalog # 29543D-5) 
was used as a template for PCR.  All PCR-derived DNA was sequenced to ensure that 
the PCR process had not introduced mutations.  
Cloning of W. succinogenes hcyS.  The hcyS gene was amplified from genomic 
DNA using standard PCR conditions and the following primer pair: 5'-ggg tag cat atg 
aat ctc atc atc aac gga gag aat aag-3' and 5'-ccc tac tcg agt tat gcg ccc cct ccc atg aaa 
tat aaa aag-3'.  The amplified product containing the gene was excised from the gel, 
purified and digested with NdeI and XhoI, repurified, and ligated into similarly 
digested and purified pTHT.   
Cloning of W. succinogenes hcyF.  The hcyF gene was amplified from 
genomic DNA using standard PCR conditions and the following primer pair: 5'-ggg 
tag cat atg aga gag ttt agc gaa gag gag cta g-3' and 5'-ccc tac tcg agt tag gga ttt tga gca 
tga ttc acc tcg cag atg ggt tgt tc-3'.  The amplified product containing the gene was 
excised from the gel, purified and digested with NdeI and XhoI, repurified, and ligated 
into similarly digested and purified pTHT.   
Cloning of W. succinogenes metY.  The metY gene was amplified from 
genomic DNA using standard PCR conditions and the following primer pair: 5'-ggg 
tag cat atg agg gga ttc acc acg agg gcg c-3' and 5'-ccc tac tcg agt taa cat agc gct tgc aaa 
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ata tcc tc-3'.  The amplified product containing the gene was excised from the gel, 
purified and digested with NdeI and XhoI, repurified and ligated into similarly 
digested and purified pTHT. 
Cloning of W. succinogenes hcyD.  The hcyD gene was amplified from 
genomic DNA using standard PCR conditions and the following primer pair: 5'-ggg 
tag cat atg ctc aaa atc cct aaa gcg ctc ttt g-3' and 5'-ccc tac tcg agt tag atc acc tcg ata ttt 
tcg gga g-3'.  The amplified product containing the gene was excised from the gel, 
purified and digested with NdeI and XhoI, repurified, and ligated into similarly 
digested and purified pTHT. 
Cloning of W. succinogenes fsr. The fsr gene was amplified from genomic 
DNA using standard PCR conditions and the following primer pair: 5'-ggg tag cat atg 
agc cac tac acc ctac ccc cct ccg tcg-3' and 5'-ccc tac tcg agt tat cgt tttt gaa tcc tca cgc 
gcc-3'.  The amplified product containing the gene was excised from the gel, purified 
and digested with NdeI and XhoI, repurified, and ligated into similarly digested and 
purified pTHT.    
Section 5.3 Expression and Purification 
 
Each of the plasmids cloned above was transformed into an expression strain 
BL21 (DE3) E. coli cells.  An overnight culture of 10 mL was grown in lysogeny 
broth media at 37°C supplemented with 50 µg/mL kanamycin, and then introduced 
into 1 L volume containing 50 µg/mL kanamycin.  The 1L cell culture was shaken at 
37°C and 200 rpm until the OD600 reached 0.6, at which point the temperature was 
reduced to 15°C and 1 mM of isopropyl-1-β-D galactopyranoside was added.  
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Approximately 16 hours later, the cells were harvested by centrifugation at 7459 g for 
20 minutes.  The pellet was stored at -80 °C. 
For each of the corresponding proteins, the same procedures were applied as 
follows.  The frozen cell pellet was thawed overnight at 4°C.  Approximately 30 mL 
of lysis buffer (20 mM Tris pH 8, 10 mM imidazole, and 333 mM NaCl) were added 
to the pellet to solubilize it.  The cell suspension was sonicated and then centrifuged at 
47, 488 g for 1 hour at 4°C to remove the cell debris.  The clarified lysate was loaded 
onto a pre-equilibrated Ni-NTA gravity column, after which the column was rinsed 
with 20 column volumes of the same lysis buffer.  The protein was eluted with an 
elution buffer (20 mM Tris pH 8, 250 mM imidazole, and 333 mM NaCl).  The eluted 
protein was loaded directly onto a size exclusion chromatography (Pharmacia G200 
superdex, hiload) column for further purification.  The protein fractions from the 
column were pooled together and concentrated to 15-25 mg/mL using an Amicon 
Ultra centrifugal filter.  Its concentration was determined by the Bradford assay 
(Sambrook et al., 1989).  The protein was confirmed by SDS-PAGE showing at least 
95% purity.  The pure protein was buffer exchanged into 20 mM Tris, pH 8 and 50 
mM NaCl, flash frozen with liquid nitrogen and stored at –80°C. 
Section 5.4 Crystallization Screening 
 
For the apo-enzymes, the frozen protein was thawed at 4°C.  For the holo-
enzymes, the thawed protein was incubated overnight with 5 mM of appropriate 
ligands made in 10 mM Tris buffer pH 8 at a stock-concentration of 1 M.  
Crystallization experiments were carried out by the vapor diffusion hanging drop 
method at 22°C, using the sparse matrix screening solutions (Hampton Research, 
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Emerald Biosystems), as well as PEG 3350/ion screen, PEG 400/pH screen, sodium 
malonate screen, ammonium sulfate/pH screen, NaCl grid screen, PEG/LiCl screen, 
PEG 8000/ion screen, and PEG 6000/pH screen.  1.5 µL of the protein solution was 
combined with an equal volume of well solution.  No hits were obtained from these 
screens.  Thus, efforts to co-crystallize the enzymes with their potential ligands were 
attempted.  Only potential ligands for HcyF and MetY are putatively known based on 
multiple sequence alignments.  Rescreening these two proteins with their 
corresponding ligands (ATP for HcyF and homocysteine/O-acetylhomoserine for 
MetY) using Wizard I, Wizard II, Hampton Research Crystal Screens 1 and 2 gave 
two hits with similar conditions, namely Wizard II conditions 39 and 43.  Condition 
43 of the Wizard II, which contains 10% PEG 8000, 0.1 M Tris pH 7, and 0.2 M 
MgCl2, gave needles that were 350 Å long and 10 Å in diameter.  They were 
optimized to bigger needle clusters using 12% PEG 8000, 0.1 M Tris pH 7.6, 0.25 M 
MgCl2, and 5% n-octyl-ß-D-maltoside.  Condition 39 of the Wizard II screen, which 
contains 10% PEG 8000 and 0.1 M imidazole pH 8.0, gave very thin but long plates 
that looked similar to needles (Figure 5.2).  
Another attempt to crystallize these proteins using in situ proteolysis gave 
showers of microcrystals of HcyF from condition 39 of Crystal Screen 2 (0.2 M 
magnesium chloride hexahydrate, 0.1 M Tris pH 8.5, and 3.4 M 1.6-hexanediol) 
(Figure 5.3).  Trypsin with a concentration of 10 mg/mL was used as the protease in a 
1:100 (v/v) ratio (the volume of trypsin was 1 µL and the protein mixture 100 µl).  
However, the crystals were not reproducible and microseeding did not generate bigger 
crystals. 
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Figure 5.2. Optimized crystals for the MetY/homocysteine complex. 
 
 
Figure 5.3.  In situ proteolysis of HcyF formed microcrystals from condition 39 of 
Crystal Screen 2. 
 
At the same time attempts to crystallize the apo-enzymes were continued using 
detergents.  However, zero hits from the long list of commercial screens mentioned 
above indicate that the normal detergent screen method, in which a hit is screened 
against 24 different detergents, was not possible.  To get around this problem, the 
detergent N, N-dimethyl dodecylamine-N-oxide (LDAO) was chosen because it is one 
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of the common detergents known to promote crystallization.  LDAO was used as an 
additive against the four commercial screens: Wizard I, Wizard II, Hampton Research 
Crystal Screen 1, and Crystal Screen 2.  One hit was obtained from condition 3 (25% 
ethylene glycol) of the Hampton Research Crystal Screen 2 for MetY.  3.0 µl of the 
protein solution was combined with 3.0 µl of well solution.  The crystals were very 
small, ranging from 25 to 50 Å in two dimensions and 50 to 75 Å in the third 
dimension.  These crystals generally have blocky shape and took approximately 90 
days to grow (Figure 5.4). 
 
Figure 5.4. Small crystals from the detergent screen after approximately 45 days. 
 
Since the C-terminus of the sulfur carrier protein HcyS must be cleaved at the 
last residue to expose the gly-gly motif before adenylation can occur, it was 
hypothesized that HcyS is probably cleaved by the putative metaloprotease HcyD.  
Attempts to crystallize the HcyS-HcyD complex were carried out.  An initial hit was 
obtained from condition 31 of Wizard I (0.1 M phosphate-citrate pH 4.2, 0.2 M NaCl, 
and 20% PEG 8000), having long thin needles (Figure 5.5).  Crystals took 
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approximately 16 days to grow and was found to be reproducible.  Current efforts are 
aimed at optimzation. 
 
Figure 5.5. Initial hit for the HcyS-HcyD complex. 
 
FSR underwent basic sparse matrix screening as an apo-enzyme, in complex 
with AMP, and as a protein-protein complex with HcyS.  So far only one hit shows 
needle clusters from condition 35 of Wizard II.  Although this condition contains 0.8 
M NaH2PO4, 1.2 M of K2HPO4, and 0.2 M sodium acetate, these needle clusters 
appear brown suggestive of iron sulfur cluster (Figure 5.6). 
 
Figure 5.6. Initial hit for apo-FSR. 
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Section 5.5 Preliminary X-ray Diffraction Analysis and Discussion 
 
The optimized condition 43 of the Wizard II screen (12% PEG 8000, 0.1 M 
Tris pH 7.6, 0.25 M MgCl2, and 5% n-octyl-ß-D-maltoside) for the 
homocysteine/MetY complex diffracted to only 8 Å resolution.  The crystals from 
condition 39 of Wizard II of the homocysteine/MetY complex also diffracted to 8 Å 
resolution.  In order to greatly improve the resolution, these crystals were screened 
against cryoreagents in addition to the commercially available additives from 
Hampton Research.  The only tested cryoreagent that significantly improved the 
crystal morphology was 2-methylpentane-2,4-diol (MPD) in a narrow range of 5-6%.  
The resulting crystals (Figure 5.2) were single plates with some thickness.  They 
improved the resolution to about 4 Å and scales in the P21 space group.  Further 
optimization is under way.  The wispy needles of the HcyS-HcyD complex in Figure 
5.5 diffracted poorly, and thus they are being optimized as well. 
Only the detergent condition of the apo-MetY crystals (Figure 5.4) that 
diffracted to a relatively high resolution was collected for structure determination. Due 
to the high concentration of ethylene glycol, no additional cryoprotection was required 
prior to data collection.  X-ray diffraction data from crystals of the apo-enzyme was 
collected at the F1 beamline outfitted with capillary focusing optics at the Cornell 
High Energy Synchrotron Source (CHESS), using an Area Detector System Corp. 
(ADSC) Quantum 270 CCD detector.  The data were collected using 0.916 Å radiation 
over 360° with 1° oscillation range. The data set was indexed, integrated, and scaled 
using the HKL2000 program suite (Otwinowski & Minor, 1997).  The diffraction 
pattern is shown in Figure 5.7.  
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Figure 5.7. Diffraction pattern that diffracted at 2.2 Å but scaled to only 4 Å at best 
 
The resolution went to 2.2 Å but the spots in the higher shells appeared very 
fuzzy (Figure 5.7).    These reflections suggest a dehydration pathology during the 
crystal transfer process.  To overcome this problem, the crystal was soaked into 
immersion oil before transfer to the goniometer.  As seen in Figure 5.8, the blurry 
spots disappeared and the reflections were well defined.  The data were collected and 
indexed to 2.2 Å.  The data collection statistics are shown in Table 5.1.  
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Table 5.1.  Data Collection Statistics for MetY. 
 MetY 
beamline F1 CHESS 
wavelength (Å) 0.916 
resolution (Å) 50-2.2 
space group C2 
Molecules / a.s.u. 2 
a (Å) 161.8 
b (Å) 62.5 
c (Å) 91.6 
α (°) 90.0 
β (°) 120.5 
γ (°) 90.0 
measured reflections 89132 
unique reflectionsa 37506 (1862) 
average <I> / <σ>a 11.0 (2.9) 
redundancya 2.4 (2.3) 
completeness (%)a 96.6 (98.2) 
Rsym (%)a,b 12.3 (40.1) 
aValues for the highest-resolution shell are given in parentheses. 
bRsym = ΣΣi | Ii − <Ι> | / Σ <Ι>, where <Ι> is the mean intensity of the N reflections 
with intensities Ii and common indices h,k,l.
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Figure 5.8.  The same diffraction pattern after soaking the crystal in immersion oil 
indexed to 2.2 Å. 
 
The data were indexed to space group C2 with two molecules per asymmetric 
unit.  Size exclusion chromatography indicated a tetrametric biological unit.  This 
experimental observation was supported by applying a two-fold crystallographic 
symmetry operation to generate a tetramer.  Further analysis using the PISA server 
(Krissinel & Henrick, 2005) confirmed that the most probable oligomeric state for 
MetY is a tetramer.  MetY is being refined using molecular replacement.  The current 
R and Rfree parameters are 23.0 and 25.7, respectively.  Water addition to the electron 
density map and ligand modeling are under way. 
 102 
REFERENCES 
 
1. Altschul, S. F., Madden, T. L., Schaffer, A. A., Zhang, J., Zhang, Z., Miller, 
W. & Lipman, D. J. (1997). Nucleic Acids Res. 25, 3389-3402. 
2. Ausubel, F. M. & Brent, F. (1987). Current Protocols in Molecular Biology. 
New York: John Wiley and Sons. 
3. Burns, K. E., Baumgart, S., Dorrestein, P. C., Zhai, H., McLafferty, F. W. & 
Begley, T. P. (2005). J. Am. Chem. Soc. 127, 11602-11603. 
4. Dorrestein, P. C., Zhai, H., McLafferty, F. W. & Begley, T. P. (2004). Chem. 
Biol. 11, 1373-1381. 
5. Duda, D. M., Walden, H., Sfondouris, J. & Schulman, B. A. J. Mol. Biol.349, 
774-786. 
6. Godert, A. M., Jin, M., McLafferty, F. W. & Begley, T. P. J. Bacteriol. 189, 
2941-2944. 
7. Krissinel, E. & Henrick, K. (2005). CompLife 163-174. 
8. Otwinowski, Z. & Minor, W. (1997). Methods Enzymol. 276, 307-326. 
9. Sambrook, J., Fritsch, E. F. & Maniatis, T. (1989). Molecular Cloning:  A 
Laboratory Manual. Plainview, New York.: Cold Spring Harbor Laboratory 
Press. 
10. Settembre, E. C., Dorrestein, P. C., Zhai, H., Chatterjee, A., McLafferty, F. W., 
Begley, T. P. & Ealick, S. E. Biochemistry 43, 11647-11657. 
 
 
 103 
CHAPTER 6  
MECHANISM OF SULFUR TRANSFER OF PROTEIN 
THIOCARBOXYLATE CATALYZED BY O-ACETYLHOMOSERINE 
SULFHYDRYLASE IN METHIONINE BIOSYNTHESIS OF WOLINELLA 
SUCCINOGENES  
Section 6.1 Introduction 
 
Wolinella succinogenes, originally found in cattle rumen, is a gram-positive 
bacterium.  Being is a member of Helicobacteraceae hepaticus, it is a close relative of 
Helicobacter pylori and Campylobacter jejuni, which are known to be harmful 
pathogens in humans and animals.  Specifically, H. pylori has been linked to ulcers 
and gastric cancer and C. jejuni has been known to cause Guillain-Barre syndrome (1).  
O-acetylhomoserine sulfhydrylase (EC 4.2.99.10) is a sulfide-utilizing enzyme in L-
cysteine and L-methionine biosynthetic pathways employed by various enteric 
bacteria and fungi.  OAHS is known to catalyze the conversion of O-acetylhomoserine 
to homocysteine using hydrogen sulfide from an unknown source (2).  While the 
source of sulfur is of great interest, the identification of this source has eluded 
researchers.  Nevertheless, recent biochemical studies in our laboratory (unpublished 
data) have revealed the likely sulfur source and led to a mechanistic proposal of the 
new pathway in Wolinella succinogenes (Figure 6.1).  A gene cluster containing genes 
for a protein thiocarboxylate, a putative metalloprotease, an adenylating enzyme, 
sulfur assimilating proteins, and proteins for methionine biosynthesis was found in this 
species.  In this proposed pathway, the sulfur of the sulfate is incorporated into  
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Figure 6.1.  Proposed pathway for sulfur assimilation in Wolinella succinogenes.  The 
blue box indicates the specific reaction discussed in this study.  The transferred sulfur 
atom is highlighted in red. 
 
adenosine-5'-phosphosulfate (APS) by an unknown enzyme.  The APS is 
phosphorylated at the 3' hydroxyl group by APS kinase to generate 3'-
phosphoadenosine-5'-phosphosulfate (PAPS), which is acted upon by PAPS reductase 
to generate sulfite.  Ferridoxin sulfite reductase (FSR) converts the sulfite to sulfide 
and transfers the sulfide to the activated, truncated HcyS protein, which has been 
truncated at the C-terminus by HcyD and adenylated by HcyF using ATP.  The 
resulting HcyS thiocarboxylate reacts with O-acetylhomoserine (OAH) catalyzed by 
MetY to form the HcyS-homocysteine adduct.  HcyD cleaves the homocysteine from 
the adduct, which is then methylated by MetE using 5-methyltetrahydrofolate as the 
cofactor to produce methionine.  As illustrated in Figure 6.1, the sulfur for 
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homocysteine in this species originated from sulfate.  In particular, the sulfur in the 
reaction catalyzed by MetY comes from a protein thiocarboxylate (HcyS-COSH) 
rather than from sulfide as previously proposed (2). 
In this study, we report the first crystal structure of OAHS at 2.2 Å resolution.  
By comparing its structure with other homologs through DALI (3), it was discovered 
that MetY has the same α/β fold as cystathionine gamma lyase (CGL) and methionine 
gamma lyase (MGL).  In addition, MetY has similar residues in the PLP binding site 
as the two lyases.  Thus, MetY belongs to the so-called Cys/Met metabolism PLP-
dependent family of enzymes, which include at least 200 enzymes from various 
species (4).  Although these enzymes are found in yeast, bacteria, and plants, none of 
them are known to exist in humans.  Therefore, this enzyme might be a potential target 
for antibiotic development.  This family of enzymes catalyzes a variety of reactions 
including γ-replacement, γ-elimination, and β-elimination (5).  The structure of MetY 
in this study, together with biochemical data, led to sub-classification of MetY as a γ-
elimination enzyme and to a mechanistic proposal of sulfur transfer via a protein 
thiocarboxylate catalyzed by MetY. 
Section 6.2 Materials and Methods 
 
Molecular Cloning of Native MetY.  Standard methods were used for DNA 
manipulations (6, 7).  Plasmid DNA was purified with the Fermentas GeneJet 
miniprep kit and DNA fragments were purified from agarose gel with the Zymoclean 
Gel DNA Recovery kit from Zymo Research.  E. coli strain MachI (Invitrogen) was 
used as a recipient for transformations during plasmid construction and for plasmid 
propagation and storage.  Phusion DNA polymerase (New England Biolabs) was used 
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for PCR following the manufacturer’s instructions.  The plasmid THT is a derivative 
of pET-28, which was obtained from Novagen.  Genomic DNA from Wolinella 
succinogenes FDC 602W (ATCC catalog # 29543D-5) was used as a template for 
PCR.  All PCR-derived DNA was sequenced to insure that the PCR process had not 
introduced mutations. 
The mety gene was amplified from genomic DNA using standard PCR 
conditions and the following primer pair: 5'-ggg tag cat atg agg gga ttc acc acg agg 
gcg c-3' and 5'-ccc tac tcg agt taa cat agc gct tgc aaa ata tcc tc-3'.  The amplified 
product containing the gene was excised from the gel, purified and digested with NdeI 
and XhoI, repurified and ligated into similarly digested and purified pTHT.  
Expression and Purification of Native MetY.  The plasmid described above was 
transformed into expression strain BL21(DE3) E. coli cells.  An overnight culture of 
10 mL was grown in lysogeny broth media at 37°C supplemented with 50 µg/mL 
kanamycin, and then introduced into 1 L volume containing 50 µg/mL kanamycin.  
The 1L cell culture was shaken at 37°C and 200 rpm until the OD600 reached 0.6, at 
which point the temperature was reduced to 15°C and 1 mM of isopropyl-1-β-D 
galactopyranoside (IPTG) was added.  Approximately 16 hours later, the cells were 
harvested by centrifugation at 7459 g for 20 minutes.  The pellet was stored at –80 °C.   
The frozen cell pellet was thawed overnight at 4°C.  Approximately 30 mL of 
lysis buffer (20 mM Tris pH 8, 10 mM imidazole, and 333 mM NaCl) were added to 
the pellet to solubilize it.  The cell suspension was sonicated and then centrifuged at 
47, 488 g for 1 hour at 4°C to remove the cell debris.  The clarified lysate was loaded 
onto a pre-equilibrated Ni-NTA gravity column, after which the column was rinsed 
with 20 column volumes of the same lysis buffer.  MetY was then eluted with 10 mL 
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of elution buffer (20 mM Tris pH 8, 250 mM imidazole, and 333 mM NaCl).  The 
eluted protein was loaded directly onto a size exclusion column (Pharmacia G200 
superdex, hiload) for further purification.  The protein fractions from the column were 
pooled together and concentrated to 25-30 mg/mL using an Amicon Ultra centrifugal 
filter.  The MetY concentration was determined by the method of Bradford (8).  The 
protein was confirmed to be at least 95% pure by SDS-PAGE.  The pure protein was 
buffer exchanged into 20 mM Tris pH 8 and 50 mM NaCl, flash frozen with liquid 
nitrogen and stored at -80°C.  
Intein Chemistry to Make HcyS-COSH.  All chemical reagents were purchased 
from Sigma-Aldrich (St. Louis, MO).  HcyS in pTYB1 was over-expressed in E. coli 
BL21(DE3).  Lysogeny broth cultures containing 100 µg/mL of ampicillin were 
grown at 37°C until an OD600 of 0.6-0.8, when the temperature was reduced to 15°C 
and the cultures were induced with a final concentration of 0.5 mM IPTG.  Further 
growth was carried out at 15°C for 12-16 h with constant agitation. The cultures were 
harvested by centrifugation and lysed by sonication on ice in 20 mM Tris, 500 mM 
NaCl, 1 mM EDTA, 0.1% (v/v) Triton X-100, pH 7.8.  The samples were then loaded 
onto a 20 mL bed volume of chitin bead column at a rate of 0.5 mL/min and washed 
with 300 mL of 20 mM Tris, 500 mM NaCl, 1 mM EDTA, pH 7.8 at rate of 2 
mL/min.  Cleavage of the protein was carried out at 4°C for 12-16 h with 30 mL of 50 
mM Na2S to give truncated HcyS-COSH.   The protein was desalted into 100 mM 
Tris, 150 mM NaCl, 2 mM TCEP, 30% glycerol, pH 8.0 by dialysis using Novagen D-
tube dialyzer Maxi (MWCO 3.5 kDa) and stored as frozen aliquots at -80°C. 
Enzymatic Reaction of HcyS-COSH with MetY and OAH.  95 µL of 159 µM 
truncated HcyS-COSH and 11 µL of 1.4 mM MetY were incubated with 1.25 µL of 10 
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mM O-acetyl-L-homoserine at room-temperature for 1 h. They were then desalted into 
50 mM ammonium acetate, pH 6.0 and analyzed by MALDI-MS. The time-period of 
incubation was reduced to 2 min when it was observed that the higher molecular-
weight 7907 Da adduct was formed. 
Crystallization Experiments.  The frozen protein was thawed at 4°C and 
incubated overnight with 5 mM homocysteine dissolved in 10 mM of Tris buffer pH 8 
at a stock-concentration of 1 M.  Co-crystallization with 5 mM homocysteine and 
OAH ligands were initially carried out by the hanging drop vapor diffusion method at 
22°C using sparse matrix screening solutions (Hampton Research, Emerald 
Biosystems). 1.5 µl of the protein solution was combined with an equal volume of 
well solution.  The homocysteine/MetY complex initially crystallized in 12% (w/v) 
PEG 8000, 0.1 M Tris pH 7.6, and 0.25 M MgCl2 and generated crystals that 
diffracted to 8 Å resolution.  Optimization of this condition against different 
precipitating agents led to a condition consisting of 10% (w/v) PEG 8000, 0.1 M 
imidazole pH 7.5, 0.2 M Mg(NO3)2, and 5% MPD.  This condition produced a new 
crystal form that diffracted to 4 Å resolution and scales in the P21 space group.  
Further optimization is underway.  For the apo-MetY, extensive screenings led to one 
condition containing 25-30% (w/v) ethylene glycol and 5% (v/v) N-dodecyl-N, N-
dimethylamine-N-oxide detergent as an additive.  The crystals were small blocks, 
ranging from 25 to 50 Å in two dimensions and 50 to 75 Å in the third dimension.  
These crystals took approximately three months to grow and were used for X-ray 
diffraction experiments. 
Data Collection and Processing.  Due to the high concentration of ethylene 
glycol, no additional cryoprotection was required prior to data collection.  X-ray 
 109 
diffraction data from crystals of the apo-enzyme was collected at the F1 beamline 
outfitted with capillary focusing optics at the Cornell High Energy Synchrotron Source 
(CHESS), using an Area Detector System Corp. (ADSC) Quantum 270 CCD detector.  
The data were collected using 0.916 Å radiation over 360° with 1° oscillation range.  
The data set was indexed, integrated, and scaled using the HKL2000 program suite 
(9).  Data collection and statistics are shown in Table 6.1. 
Structure Determination.  The MetY structure was solved by molecular 
replacement using MOLREP (10) and the TtOAHS structure (2CTZ) as the search 
model (11).  CHAINSAW (12) was used to remove all side chains of the search model 
that were not  conserved in the sequence alignment with MetY.  Refinement was 
performed using REFMAC (13), and alternated with successive manual model 
building using COOT (14) guided by mFo-DFc, map, 2fo-fc map, and composite omit 
electron density maps generated using CNS (15) .  Water molecules were added after 
the Rfactor and Rfree converged.  The geometry of MetY was validated using 
PROCHECK (16).  All figures were produced using Pymol and ChemBioDraw (17).  
Refinement statistics are tabulated in Table 6.2. 
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Table 6.1.  Data Collection Statistics for MetY. 
 MetY 
beamline F1 CHESS 
wavelength (Å) 0.916 
resolution (Å) 50-2.2 
space group C2 
Molecules / a.s.u. 2 
a (Å) 161.8 
b (Å) 62.5 
c (Å) 91.6 
α (°) 90.0 
β (°) 120.5 
γ (°) 90.0 
measured reflections 89132 
unique reflectionsa 37506 (1862) 
average <I> / <σ(I)>a 11.0 (2.9) 
redundancya 2.4 (2.3) 
completeness (%)a 96.6 (98.2) 
Rsym (%)a,b 12.3 (40.1) 
aValues for the highest-resolution shell are given in parentheses. 
bRsym = ΣΣi | Ii − <Ι> | / Σ <Ι>, where <Ι> is the mean intensity of the N reflections 
with intensities Ii and common indices h,k,l. 
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Table 6.2.  Data Refinement Statistics for MetY. 
 
 MetY 
resolution (Å) 50-2.2 
no. of protein atoms 5355 
no. of water atoms 163 
reflections in working set 38264 
reflections in test set 2565 
R-factora (%) 23.0 
Rfreeb (%) 25.7 
rmsd from ideals  
bonds (Å) 0.017 
angles (°) 1.831 
avg B factor (Å2) 23.1 
Ramachandran Plot  
most favored (%) 92.7 
additionally allowed (%) 7.1 
generously allowed (%) 0.0 
disallowed (%) 0.2 
  
aR-factor = Σhkl| |Fobs| − k |Fcal| | / Σhkl |Fobs| where Fobs and Fcal are observed and 
calculated structure factors, respectively. 
bFor Rfree, the sum is extended over a subset of reflections (5%) excluded from all 
stages of refinement. 
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Section 6.3 Results 
 
 
Enzymatic Reaction of HcyS-COSH with MetY/PLP and OAH.  MetY was 
tested as a possible enzyme for homocysteine biosynthesis.  Figure 6.2A illustrates 
this reaction, in which HcyS-COSH was synthesized using intein chemistry.  Analysis 
by MALDI-TOF after incubation of HcyS-COSH with MetY and OAH for 2 minutes, 
revealed a new peak (Figure 6.2B).  A single dominant peak was observed with a 
molecular weight of 7810 Da in the graph of normalized intensity versus mass per unit 
charge. 
 
Figure 6.2.  (A) The proposed reaction and the expected molecular weights catalyzed 
by MetY. (B) the MALDI mass spectrum for HcyS-homocysteine adduct.  
 
Crystal Structure of MetY.  The unit cell was calculated to have a Matthews 
coefficient of 2.23 for two molecules in the asymmetric unit, which corresponds to a 
solvent content of 44.8%.   Although only two subunits are found in the asymmetric 
unit (Figure 6.3A) the biological unit of MetY appears to be a homotetramer (Figure 
6.3D), based on size exclusion chromatography data.  Each subunit contains an active 
site and thus there are four active sites per tetramer.  These are arranged such that the 
active site of each monomer faces one side and the two active sites of adjacent 
 113 
monomers face the opposite side.  The dimension of the monomer is approximately 50 
x 50 x 70 Å and the tetramer 95 x 85 x 75 Å.  The average interface surface area 
between any two adjacent pair of monomers is about 1018 Å2 for a given average 
monomeric surface area of 15127 Å2 as calculated by the PISA server (18). 
 
Figure 6.3.  Structures of MetY.  (A) Dimer observed in the asymmetric unit. (B) 
Monomer with labeled and numbered secondary structures. (C) Topology diagram 
containing the same labels as in (B. (D) The biological tetramer. PLP is represented as 
spheres.  Letters N and C in the topology diagram denote N- and C-termini. 
 
Monomeric Subunit of MetY.  The monomer has the α/β fold and consists of a 
large central seven-stranded beta sheet, a two-stranded sheet, and a three-stranded 
sheet.  All of these sheets are flanked by a total of ten 10 alpha helices and two 310 
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helices (Figures 6.3B, 6.3C).  Each monomer contains one PLP cofactor and 407 
amino acids.  The electron density for two segments was absent in the structure of 
MetY.  The longer segment is located at the N-terminus and is comprised of about 50 
residues while the smaller one is at the C-terminus and consists of about 10 residues.  
The monomer is composed of at least two domains.  The large domain contains the 
PLP binding site and is comprised of the seven-stranded beta sheet, which is flanked 
on both sides by α2, α3, α4, α5, α6, α7, α8, η1, η2, and part of α9.  Six of the seven 
strands, β1-β6, in the large sheet are parallel and one is anti-parallel (β9).  The smaller 
domain resides near the C-terminal end and contains a slightly twisted anti-parallel 
three-stranded sheet, which is flanked on both sides by α9, α10, α11, and α12.  β7 
and β8 are continuous with β6 and β9 and extend to form another small sheet. α9 is an 
extremely long helix, consisting of 34 residues and spanning the two domains.  The 
compact monomer is achieved by the tight packing between the two domains. 
Active Site of MetY.  While the enzyme was crystallized without any substrates 
bound, the active site was easily located based on structural homology to 
Pseudomonas putida MGL (PpMGL), and yeast CGL (yCGL) (5, 19).  The search for 
the active site was facilitated by the fact that the space occupied by the active site is 
relatively large and open to the solvent.  The stereo drawing and schematic illustration 
of the active site are shown in Figures 6.4A and 6.4B, respectively.  The PLP cofactor 
was manually positioned in the active site in order to identify important residues.  The 
active site is located near the N-terminus of α3.  In the absence of PLP, the active site 
is filled with water molecule.  Without PLP in the active site, Thr204, Lys205, and 
F108 shift significantly from their assumed positions based on structural alignment of  
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Figure 6.4.  The active site of MetY in stereo (A) and schematic (B).  The PLP 
cofactor shown in cyan and red, respectively, in both panels is manually positioned in 
the active site based on superposition of structural homologs.  The dashed lines 
indicate possible hydrogen bonds and letter 'W' water molecule. 
 
the homologs.  The phosphate group of PLP potentially makes hydrogen bonds with 
Thr204, Ser202, and the amide hydrogen atoms of Gly83 and Met84.  Asp180 is 
within salt bridge distance to the N1H of PLP.  Leu353, Met183, I87, and Met84 
could interact with the hydrophobic region of PLP.  Glu151 does not appear to interact 
directly with the PLP but makes a hydrogen bond to Phe108, which could stabilize the 
pyridine ring of PLP by π-stacking interaction.  Thr182 and Ser202 are about 3 Å 
directly below the plane of the PLP’s pyridine ring according to the orientation shown 
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in Figure 6.4.  These two residues hydrogen bond with the π-electron ring of the 
pyridine ring of PLP.  In addition, Thr182 also hydrogen bonds to Asp180.  No 
residues in the active site appear to interact with the methyl group of PLP.  The 
hydroxyl group of PLP hydrogen bonds to an ordered water molecule in the structures 
of the homologs.  Hence, the same might be the case for the PLP of MetY.  With 
exception of the residues missing from the structure, all of the residues that bind PLP 
originate from the large PLP binding domain. 
Section 6.4   Discussion 
 
Enzymatic Reaction of HcyS-COSH with MetY/PLP and OAH.  Recent 
literature (20-22) has demonstrated that CysO thiocarboxylate in cysteine biosynthetic 
pathway of Mycobacterium tuberculosis is converted to CysO-cysteine adduct by 
PLP-dependent O-phospho-L-serine sulfhydrylase or CysM and O-phospho-L-serine.  
Thus, if MetY catalyzes a similar reaction as that of CysM using PLP as a cofactor, 
OAH, and HcyS-COSH substrates, then the expected product is the HcyS-
homocysteine adduct with a molecular weight of 7806 Da.  A single peak of the 
MALDI spectrum on Figure 6.2B shows the expected mass of 7810 Da, which is well 
within experimental error.  This confirms that MetY utilizes a similar catalytic 
mechanism as CysM.  Furthermore, the HcyS-homocysteine adduct was shown to be 
cleaved by HcyD to release homocysteine, which was characterized by NMR and 
HPLC (unpublished data). 
Structure of MetY.  Although the asymmetric unit contains a dimer, the 
tetramer can be generated by a two-fold symmetry operation on the dimer.  This 
structure was confirmed by the PISA server (18) (Figure 6.3).  Furthermore, the 
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OAHS from Schizosaccharomyces pombe was also shown biochemically to be 
tetrameric (23).  The arrangement of the subunits of MetY is not uniform and the 
diagonal subunits of the tetramer do not interact.  Each monomer of the tetramer packs 
differently against two adjacent monomers.  Specifically, each monomer of the 
tetramer interacts intimately with one adjacent monomer primarily via a long loop, α3, 
α4, and α8.  The two active sites of these two monomers are about 20 Å apart and 
they are equivalent to the so-called active dimer in PpMGL, and yCGL (5, 19).  The 
interaction of the same monomer with the other adjacent monomer involves primarily 
short loops, α1 and α9.  The active sites of these latter two monomers are about 37 Å 
apart.   
With the exception of the missing residues in the N-terminus, the monomer 
contains two domains: the large PLP binding domain and the small C-terminal 
domain.  A search using the DALI server (3) identified several structural homologs.  
The top representative hits are tabulated in Table 6.3.  The top hit with a Z-score of 
45.4 and aligned sequence identity of 41% comes from TtOAHS, the molecular 
replacement search model.  The next two representative hits with a Z-score of 41.9 
belong to the Cys/Met metabolism PLP-dependent family of enzymes, specifically 
CGL and MGL.  This family of enzymes utilizes PLP to carry out β-elimination, γ-
elimination, and γ-replacement reactions (5).   MGL and CGL also function 
biologically as a tetramer (5, 19, 24, 25).  The high degree of similarity suggests that 
MetY most likely performs the same type of γ-elimination reaction as those enzymes.  
In addition, the missing N-terminal residues in MetY most likely constitute the third 
domain that was observed in structures of γ-elimination enzymes.  These residues are 
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known to stabilize the active dimer-dimer interface (19), which may explain why only 
one active dimer is found in the asymmetric unit of MetY.   
Table 6.3.  Enzymes Structurally Similar to MetY as Evidenced by DALI. 
 
protein PDB 
ID 
Z 
score 
rmsd % identical no. 
aligned 
residues 
no.  
residues 
OAHS 2CTZ 45.4 1.7 41 344 421 
CGL 3E6G 41.9 1.5 33 322 368 
MGL 1GC2 41.9 1.8 38 325 370 
 
One residue, Tyr187, is in the disallowed region of the Ramachandran plot.  
Tyr187 has clear electron density at 2.2 Å resolution allowing for its unambiguous 
placement.  This bulky side chain is part of the helix turn and this probably explains 
why it was slightly twisted into an unfavorable conformation. 
Comparison of MetY with its Structural Homologs.  Primary sequence 
alignment (26, 27) of MetY against TtOAHS, PpMGL, and yCGL (Figure 6.5) shows 
that these sequences have relatively high sequence identity.  The first 58 residues vary 
the most among the four species.  This N-terminal domain was proposed to play a role 
in substrate recognition among the MGL family of enzymes (19).  An insertion of 19 
and 26 amino acids for MetY and TtOAHS, respectively, starting at residue 241 of 
MGL may be unique for OAHSs.  The result of this insertion is very obvious when 
viewing superimposed structures of these enzymes (Figure 6.6).  The insertion in 
MetY covers η2, α7, and the loop between them and might differentiate OAHSs from 
other Cys/Met metabolism PLP-dependent enzymes.  The conserved residues marked  
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Figure 6.5.  Sequence alignment of MetY with TtOAHS (2CB1), yeast CGL (1N8P), 
and PpMGL (2O7C).  The conserved active sites residues are marked with green 
ellipses, and other active site residues of MetY with cyan ellipses.  The two conserved 
residues that bind to the phosphate group of adjacent monomer’s PLP are marked with 
blue ellipses.  The numbering scheme is based on the sequence of PpMGL.
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with blue ellipses are only observed in the MGL and CGL structures (5, 19) but not in 
TtOAHS and MetY.  These residues of PpMGL and yCGL bind to the phosphate 
group of PLP of an adjacent monomer.  Hence, the equivalent residues from each 
monomer of TtOAHS and MetY probably bind to the phosphate group of PLP of an 
adjacent monomer as well.  This implies that each subunit requires two conserved 
residues from the adjacent monomer of the active dimer.  Thus, the minimal functional 
unit is the active dimer.  Figure 6.6 demonstrates that these enzymes have nearly 
identical structures despite sharing only 33-41 percent identity.  As illustrated in Table 
6.3, the r.m.s. distance ranges from 1.5 to 1.8 Å for 322 to 344 aligned residues.  
These results suggest that MetY, MGL, TtOAHS, and CGL probably evolved from a 
common ancestral enzyme.   
 
Figure 6.6.  Structural superposition of the monomer of MetY (green) with that of 
TtOAHS (2CB1, blue), yeast CGL (1N8P, magenta), and PpMGL (2O7C, grey).  The 
PLP molecule is shown using spheres. 
 
Comparison of the MetY Active Site with Structural Homologs.  Since MetY, 
TtOAHS, PpMGL, yCGL share the same fold it is of interest to compare their active 
sites.  In fact, superposition of the active sites (Figure 6.7) of these homologs and  
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Figure 6.7.  Superposition of the active sites of MetY with the same set of enzymes in 
Figure 6.6 using the same coloring scheme, except that the color of PLP is the same as 
its corresponding enzyme.  Residues marked with an asterisk come from a neighboring 
monomer. 
 
MetY allowed the identification of the active site of MetY.  As expected, the active 
site residues are relatively conserved.  In addition to our biochemical data, which show 
that MetY needs PLP for activity, MetY appears yellow in the color of PLP 
throughout the purification procedures.  PLP must have dissociated from the active 
site during crystallization under these conditions.  By comparing the active site 
residues of MetY with TtOAHS (2CB1), PpMGL (19), and yCGL (5), the active site 
residues of MetY can be easily identified.  The equivalent residues to Phe108 of MetY 
in the other three structures form π-stacking interactions with the pyrimidine ring of 
PLP, and thus increase the electron sink capacity of PLP (28, 29).  Hence, Phe108 is 
presumed to possess the same role.  The conserved Glu151 does not interact directly 
with the PLP but hydrogen bonds to the amide backbone of Phe108 and positions it in 
the active site.  In the absence of PLP, Phe108 is oriented slightly off from the 
pyrimidine ring of PLP.  The conserved Thr182 and Ser202 form van der Waals 
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interactions with the PLP’s pyridine ring as well as hydrogen bonds to the π-electron 
ring.  Together with Phe108, Thr182 and Ser202, they sandwich or lock PLP in the 
active site.  Thr182 also hydrogen bonds to the amide hydrogen of the conserved 
Asp180 to presumably position it to make the salt bridge with N1H of PLP.  This 
presumed salt bridge helps increase the electrophilicity of the pyridine ring of PLP.  
The equivalent residues of the conserved Lys205 covalently link to PLP, and those of 
the conserved Thr204 and Ser202 residues make hydrogen bonds with the phosphate 
group of PLP.  As for Phe108, both Lys205 and Thr204 move away from the active 
site in the absence of PLP.  In fact, the active site is wide open to the solvent in the 
absence of PLP as shown by surface representation in Figure 6.8.  The backbone 
amide groups of the Met84 and the conserved Gly83 are in position to hydrogen bond 
to the phosphate group of PLP.  The conserved R387 makes no direct contact with 
PLP but its equivalents in PpMGL and yCGL are known to bind to the carboxylate 
group of incoming substrates (5, 19).  Leu353, Met183, I87, and Met84 are in position 
to interact with the hydrophobic region of PLP.  No residues in the active site appear 
to interact with the methyl group of PLP. 
 
Figure 6.8.  Surface representation of a subunit of MetY showing a PLP (sticks) 
molecule manually positioned in the active site. 
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Mechanistic Implications.  The primary sequence and structural alignments of 
MetY against its homologs suggests that MetY belongs to the Cys/Met metabolism 
PLP-dependent family of enzymes, which includes CysO and CysM.  Our biochemical 
and structural data suggest that HcyS and MetY can perform the same catalytic 
mechanism of sulfur transfer in making homocysteine and subsequently methionine.  
Furthermore, the active site of MetY of the tetramer is very accessible to the C-
terminus of HcyS (Figure 6.8).  If MetY and HcyS were to form a complex, the ratio 
of the two must be 1:1.  From the biochemical data and the structure of MetY, the 
mechanism of sulfur transfer to generate the HcyS-homocysteine adduct is proposed 
(Figure 6.9).  In this proposal, Lys205 of MetY is covalently linked to PLP by an 
internal aldimine 1 which, as seen in its structural homologs, reacts with OAH to 
generate 2.  All the nucleophiles are assumed to be deprotonated by a nearby base 
before adding to an electrophile.  Intermediate 2 liberates Lys205 to produce 3.  The 
external aldimine 3 is tautomerized to generate 4, and then 5, which undergoes γ-
elimination to make 6.  HcyS thiocarboxylate attacks the activated conjugated double 
bond to form 7, which is tautomerized to 8, and then 9.  Lys205 covalently reattaches 
to PLP (10) to regenerate the internal aldimine 1 and release 11, which undergoes S, 
N-acyl shift to form the HcyS-homocysteine adduct. 
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Figure 6.9.  Mechanistic proposal for the sulfur transfer from HcyS-COSH to OAH 
catalyzed by MetY.  The sulfur atom is highlighted in red for clarity. 
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Significance.  This mechanistic study of MetY, together with the structure of 
TtOAHS, suggests that MetY, and perhaps all OAHSs, belong to the Cys/Met 
metabolism PLP-dependent family of enzymes.   The facts that CysM does not have 
the same fold nor active site geometry as those of MetY (22, 30), is about 85 residues 
shorter than MetY, and catalyzes β-elimination of CysO (22) suggest that MetY 
belongs to the γ-elimination subclass of the Cys/Met metabolism PLP-dependent 
family of enzymes.  In other words, our studies uncover the ability of MetY, and 
perhaps all OAHSs, to catalyze γ-elimination reactions in addition to the known 
function of direct sulfide utilization to produce homocysteine via the direct 
sulfhydrylation pathway.  This study also broadens our understanding of the 
mechanism by which the class of protein thiocarboxylate, such as HcyS-COSH, 
transfers sulfur to small molecules. 
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CHAPTER 7  
 SUMMARY AND CONCLUSIONS 
The work from Chapter 2 reports the crystal structures of SpUP in complex 
with the products (R1P/Ura) as well as the substrate (Urd) determined at 1.8 Å and 2.2 
Å resolution, respectively.  The structures reveal that SpUP has the same overall 
monomeric fold as that of NP-I family of enzymes.  Comparing the active site of 
SpUP with EcUP suggests that the two enzymes have the same transition state.  
However, SpUP utilizes different residues to stabilize the negative charge on the base.  
A multiple sequence alignment of SpUP against representative UPs reveals that among 
all the representative species in the alignments, 22 out of 53 sequences contain the Lys 
and His residues equivalent to K162 and H169 of SpUP.  None of these have the 
equivalents of Arg168 and Arg223 of EcUP.  The other 31 sequences, including 
EcUP, show the reverse.  These 31 enzymes possess the two equivalent arginine 
residues, but none of them have the equivalent K162 and H169 of SpUP.  These 
results not only suggest a new way of clustering of UP's but also uncovers a subclass 
of UP’s that utilize different active-site residues to stabilize the transition state.  The 
two discriminating residues, Lys162 and His169, together with UP's specificity loop 
may be used to distinguish between UP and PNP enzymes at the level of primary 
sequence, and thus may allow proper annotation. 
The crystal structures of the bPNP/M1G-dR/PO4 and bPNP/M1G-dR/SO4 
complexes in Chapter 3 were determined at 2.4 Å resolution.  Although the electron 
density for the sugar moiety for both complexes is weak, it clearly shows the presence 
of M1G in the active site.  One surprising result was that the sulfate ion cleaved M1G-
dR into a glycal intermediate and the M1G base.  The active sites of bPNP/M1G-
dR/PO4 and bPNP/M1G-dR/SO4 complexes were described individually and 
compared.  The comparison reveals that both the phosphate and the sulfate ions can 
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cleave M1G-dR.  A comparison of the structure of the bPNP/M1G-dR/SO4 complex 
with the EcPNPinosine/SO4 complex, showed that the Glu201 residue of bPNP, which 
is nearly coplanar with M1G in the base binding pocket, could not make an 
indispensable hydrogen bond to M1G.  This most likely destabilized M1G-dR and 
facilitated the unexpected cleavage by the sulfate ion.  This unfavorable van der Waals 
interaction most likely induced the bond cleavage and prevented the bond formation.  
These comparisons may explain why bPNP can only catalyze the cleave of M1G-dR  
but not its synthesis.    
Chapter 4 shows step-by-step the entire design and synthesis of a light-
activated inhibitor based on the known crystal structure of the ThiS-ThiG complex.  
The analog was successfully synthesized in relatively good yield measured by 
Ellman's assay.  We also demonstrated the proof-of-concept to covalently link an 
aminothiol ligand to ThiS using intein chemistry.  In particular, we have shown that 
ThiS can be covalently linked to compounds 37, 44, and 46 to give 39, 45, and 47, 
respectively, and confirmed the resulting covalent adducts using ESI-MS and FT-MS.  
The objective of future studies is to attach compound 59 to ThiS using intein 
chemistry to generate 69.  Photolysis of 69 using Hanovia lamp in the presence of 
ThiG should regenerate methyl ketone 27 and facilitate the Schiff base linkage with 
Lys96 of ThiG to produce 28.  Sodium borohydride reduction of 28 will trap the 
proposed analog 4, which will be confirmed by SDS PAGE, FT-MS, and X-ray 
crystallography. 
In Chapter 5, the crystallization and diffraction screenings of selected enzymes 
in the methionine biosynthetic and sulfur assimilation pathways of Wolinella 
succinogenes were described.  The crystallization conditions for the 
MetY/homocysteine complex was optimized from 8 Å to 4 Å resolution by screening 
with different cryoreagents.  In situ proteolysis, gave showers of microcrystals for 
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HcyF protein.  However, these crystals were not reproducible by this method and 
microseeding from these microcrystals, so far, has not been not successful.  The 
condition for HcyS-HcyD complex generates reproducible needles but these crystals 
diffracted poorly.  Initial sparse matrix screens gave one hit from condition 35 of 
Wizard II.  Although this condition contains 0.8 M NaH2PO4, 1.2 M of K2HPO4, and 
0.2 M sodium acetate, these needle clusters appear brown suggestive of iron sulfur 
cluster.  Detergent screens for the apo-MetY produced small crystals that diffracted to 
2.2 Å resolution.  These crystals were used for X-ray diffraction experiments.  
However, the initial data set appeared very fuzzy at high resolution, suggesting a 
dehydration pathology.  To overcome the problem, the crystals were soaked into 
immersion oil before transfer to the goniometer.  The images became clear and thus 
the data were collected and indexed to space group C2.  Further optimizations of the 
rest of the hits are in progress. 
Chapter 6 reports the first crystal structure of OAHS or MetY at 2.2 Å 
resolution.  By comparing its structure with other homologs, it was discovered that 
MetY has nearly a identical α/β fold to CGL and MGL.  In addition, MetY has similar 
residues in the PLP binding site as the two lyases.  Thus, MetY belongs to the 
Cys/Met metabolism PLP-dependent family of enzymes.  The fact that CysM has 
meither the same fold nor active site geometry as MetY, is about 85 residues shorter 
than MetY, and catalyzes β-elimination of CysO suggest that MetY belongs to the γ-
elimination subclass of the Cys/Met metabolism PLP-dependent family of enzymes.  
In other words, our studies uncover the ability of MetY, and perhaps all OAHSs, to 
catalyze γ-elimination reactions in addition to the known function of direct sulfide 
utilization to produce homocysteine via the direct sulfhydrylation pathway.  This study 
also broadens our understanding of the mechanism by which the class of protein 
thiocarboxylate, such as HcyS-COSH, transfers sulfur to small molecules. 
